<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        16-828-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NIMENRIX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TETANUS TOXOID,MENINGOCOCCAL GROUP A (NEISSERIA MENINGITIDIS) POLYSACCHARIDE VACCINE,MENINGOCOCCAL GROUP C (NEISSERIA MENINGITIDIS) POLYSACCHARIDE,MENINGOCOCCAL GROUP W (NEISSERIA MENINGITIDIS) POLYSACCHARIDE,MENINGOCOCCAL GROUP Y (NEISSERIA MENINGITIDIS) POLYSACCHARIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        44,5,5,5,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        158.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Belgium N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Belgium N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07AH08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nimenrix is a vaccine which helps protect against infections caused by bacteria (germs) called &ldquo;<em>Neisseria meningitidis&quot; </em>types A, C, W-135 and Y<em>.</em></p><p><em>&ldquo;Neisseria meningitidis&quot; </em>types A, C, W-135 and Y bacteria can cause serious illnesses such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; meningitis - an infection of the tissue that lines the brain and spinal cord.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; septicaemia - an infection of the blood.</p><p>These infections are passed easily from person to person and can cause death if not treated.</p><p>Nimenrix may be given to adults, adolescents, children and infants over the age of 6 weeks.</p><p>&nbsp;</p><p><strong>How Nimenrix works</strong></p><p>Nimenrix helps your body to produce its own protection (antibodies) against the bacteria. These antibodies help protect you against the diseases.</p><p>Nimenrix will only protect against infections caused by the bacteria &ldquo;<em>Neisseria meningitidis&rdquo;</em> types A, C, W-135 and Y.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Nimenrix should not be given if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to the active substances or any of the other ingredients in this vaccine (listed in section 6).</p><p>Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue. <strong>See your doctor immediately if you notice any of these</strong>.</p><p>If you are not sure, talk to your doctor or nurse before you receive Nimenrix.</p><p>&nbsp;</p><p><strong>Warnings and precautions:</strong></p><p>Check with your doctor or nurse before you receive this vaccine if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an infection with a high temperature (over 38&deg;C). If this applies to you, the vaccination will not be given until you are feeling better. A minor infection such as a cold should not be a problem. However, talk to your doctor or nurse first.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a bleeding problem or you bruise easily.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or nurse before you receive Nimenrix.</p><p>&nbsp;</p><p>Nimenrix may not fully protect everyone who is vaccinated. If you have a weak immune system (such as due to HIV infection or medicines that affect the immune system) you may not get a full benefit from Nimenrix.</p><p>&nbsp;</p><p>Fainting can occur (mostly in adolescents) following, or even before, any needle injection. Therefore tell the doctor or nurse if you or your child fainted with a previous injection.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Nimenrix</strong></p><p>Tell your doctor or nurse if you are taking or have recently taken any other medicines, including other vaccines and medicines obtained without a prescription.</p><p>&nbsp;</p><p>Nimenrix may not work as well if you are taking medicines that affect your immune system.</p><p>&nbsp;</p><p>In infants, Nimenrix can be given concomitantly with combined diphtheria - tetanus - acellular pertussis (DTaP) vaccines, including combination DTaP vaccines with hepatitis B, inactivated poliovirus or <em>Haemophilus influenzae</em> type b (HBV, IPV or Hib) such as DTaP-HBV-IPV/Hib vaccine, and with 10-valent pneumococcal conjugate vaccine.</p><p>&nbsp;</p><p>From age 1 year and above, Nimenrix can be given concomitantly with any of the following vaccines: hepatitis A (HAV) and hepatitis B (HBV) vaccines, measles - mumps - rubella (MMR) vaccine, measles - mumps - rubella - varicella (MMRV) vaccine, 10-valent pneumococcal conjugate vaccine or unadjuvanted seasonal influenza vaccine.</p><p>&nbsp;</p><p>In the second year of life, Nimenrix can also be given concomitantly with combined diphtheria - tetanus - acellular pertussis (DTaP) vaccines, including combination DTaP vaccines with hepatitis B, inactivated poliovirus or <em>Haemophilus influenzae</em> type b (HBV, IPV or Hib) such as DTaP-HBV-IPV/Hib vaccine, and 13-valent pneumococcal conjugate vaccine.</p><p>&nbsp;</p><p>In individuals aged 9 to 25 years, Nimenrix can be given concomitantly with human papillomavirus vaccine [Types 16, 18] and a combined diphtheria (reduced antigen content), tetanus and acellular pertussis vaccine.</p><p>&nbsp;</p><p>Whenever possible, Nimenrix and a TT containing vaccine, such as DTaP-HBV-IPV/Hib vaccine, should be co-administered or Nimenrix should be administered at least one month before the TT containing vaccine.</p><p>&nbsp;</p><p>A different injection site will be used for each vaccine.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant, think you may be pregnant, plan to become pregnant or are breast-feeding, you must tell your doctor before receiving Nimenrix.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Nimenrix is not likely to affect your ability to drive or use machines. However, do not drive or use any machines if you are feeling unwell.</p><p>&nbsp;</p><p><strong>Nimenrix contains sodium</strong></p><p>This vaccine contains less than 1 mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nimenrix will be given to you by a doctor or nurse.</p><p>Nimenrix is always injected into a muscle, usually in the upper arm or thigh.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Primary immunisation</em></p><p>&nbsp;</p><p><u>Infants from 6 weeks to less than 6 months of age </u></p><p>Two injections given 2 months apart at e.g. 2 and 4 months of age (the first injection may be given from the age of 6 weeks).</p><p>&nbsp;</p><p><u>Infants from 6 months of age, children, adolescents and adults</u></p><p>One injection.</p><p><em>&nbsp;</em></p><p><em>Booster doses</em></p><p><em>&nbsp;</em></p><p><u>Infants from 6 weeks to less than 12 months of age: </u></p><p>One booster dose at 12 months of age, at least 2 months after the last dose of Nimenrix.</p><p>&nbsp;</p><p><u>Previously vaccinated individuals 12 months of age and older</u>:</p><p>Please tell your doctor if you have received a previous injection with another meningococcal vaccine than Nimenrix.</p><p>Your doctor will tell you if and when you need an additional dose of Nimenrix, especially if you or your child:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; received your first dose at age 6-14 months and could be at particular risk of infection caused by <em>Neisseria meningitidis</em> types W-135 and Y</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; received your dose more than approximately one year ago and could be at risk of infection caused by<em> Neisseria meningitidis</em> type A</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; received your first dose at age 12-23 months and could be at particular risk of infection caused by <em>Neisseria meningitidis</em> types A, C, W-135 and Y</p><p>&nbsp;</p><p>You will be informed when you or your child should come back for the next injection. If you or your child misses a scheduled injection, it is important that you make another appointment.</p><p>&nbsp;</p><p>Make sure you or your child finishes the complete vaccination course.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>&nbsp;</p><p><strong>Very common (these may occur with more than 1 in 10 doses of the vaccine):</strong></p><ul><li>fever</li><li>tiredness (fatigue)</li><li>headache</li><li>feeling drowsy</li><li>loss of appetite</li><li>feeling irritable</li><li>swelling, pain and redness where the injection is given.</li></ul><p>&nbsp;</p><p><strong>Common (these may occur with up to 1 in 10 doses of the vaccine):</strong></p><ul><li>bruising (haematoma) where the injection is given</li><li>stomach and digestion problems such as diarrhoea, vomiting and nausea</li><li>rash (infants).</li></ul><p>&nbsp;</p><p><strong>Uncommon (these may occur with up to 1 in 100 doses of the vaccine):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; crying</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aching muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the arms or legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generally feeling unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased feeling or sensitivity, especially in the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactions where the injection is given such as itching, a feeling of warmth or numbness or a hard lump.</p><p>&nbsp;</p><p><strong>Rare (these may occur up to 1 in 1,000 doses of the vaccine):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (seizures) associated with a high temperature</p><p>&nbsp;</p><p><strong>Not known:</strong> frequency cannot be estimated from the available data</p><ul><li>injection site swelling and redness; this may affect a large area of the vaccinated limb</li><li>enlarged lymph nodes</li></ul><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to National Pharmacovigilance Centre (NPC). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects: </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are:</p><ul><li>After reconstitution, 1 dose (0.5&nbsp;ml) contains:</li><li>Neisseria meningitidis group A polysaccharide1 5&nbsp;micrograms</li><li>Neisseria meningitidis group C polysaccharide1 5&nbsp;micrograms</li><li>Neisseria meningitidis group W-135 polysaccharide1&nbsp;&nbsp;&nbsp;&nbsp; 5&nbsp;micrograms</li><li>Neisseria meningitidis group Y polysaccharide1 5&nbsp;micrograms</li><li>1conjugated to tetanus toxoid carrier protein&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44&nbsp;micrograms</li></ul><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the powder: sucrose and trometamol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the solvent: sodium chloride (see section 2 &ldquo;Nimenrix contains sodium&rdquo;) and water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nimenrix is a powder and a solvent for solution for injection.
Nimenrix is supplied as a white powder or cake in a single dose glass vial and a clear and colourless solvent in a pre-filled syringe.
These must be mixed together before use. The mixed vaccine will appear as a clear colourless solution.
Nimenrix is available in packs of 1 or 10 with or without needles.

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>Marketing Authorisation Holder </u></strong></p><p><strong><u>&nbsp;</u></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Pfizer Europe MA EEIG, Belgium</p><p>&nbsp;</p><p><strong>Manufactured by</strong></p><p>Pfizer Manufacturing Belgium NV<br />Puurs, Belgium&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>-------------------------------------------------------------------------------------------------------------------------</p><p>The following information is intended for healthcare professionals only:</p><p>&nbsp;</p><p>The vaccine is for intramuscular use only. Do not administer intravascularly, intradermally or subcutaneously.</p><p>&nbsp;</p><p>If Nimenrix is co-administered with other vaccines, different injection sites should be used.</p><p>&nbsp;</p><p>Nimenrix should not be mixed with other vaccines.</p><p>&nbsp;</p><p><strong>Instructions for reconstitution of the vaccine with the solvent presented in pre-filled syringe:</strong></p><p>&nbsp;</p><p>Nimenrix must be reconstituted by adding the entire content of the pre-filled syringe of solvent to the vial containing the powder.</p><p>To attach the needle to the syringe, refer to the picture. However, the syringe provided with Nimenrix might be slightly different (without screw thread) than the syringe described in the picture. In that case the needle should be attached without screwing.</p><p>&nbsp;</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holding the syringe <strong><u>barrel</u></strong> in one hand</p><p>(avoid holding the syringe plunger),</p><p>unscrew the syringe cap by twisting it anticlockwise.</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Syringe plunger</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Syringe barrel</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Syringe cap</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To attach the needle to the syringe,</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; twist the needle clockwise into the syringe</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; until you feel it lock (See picture).</p><p>&nbsp;</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the needle protector, which on</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Needle protector</p></td></tr></tbody></table><p>occasion can be a little stiff.</p><p>&nbsp;</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add the solvent to the powder. After the addition of the solvent to the powder, the mixture should be well shaken until the powder is completely dissolved in the solvent.</p><p>&nbsp;</p><p>The reconstituted vaccine is a clear colourless solution.</p><p>The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.</p><p>After reconstitution, the vaccine should be used promptly.</p><p>&nbsp;</p><p>A new needle should be used to administer the vaccine.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>THIS IS A MEDICAMENT</strong></p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the Pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor and the Pharmacist are experts in medicines, their benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p><strong>Keep all medicaments out of reach and sight of children</strong></p><p><strong>&nbsp;</strong></p><p><strong>Council of Arab Health Ministers</strong></p><p><strong>Union of Arabic Pharmacist</strong></p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                February 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>نيمنريكس هو لقاح يساعد في الوقاية من حالات العدوى التي تسببها بكتيريا (جراثيم) تُسمى &quot;النيسرية السحائية (نيسيريا مينينجيتيديس)&quot; من الأنواع A، وC، وW-135، وY&rlm;<em>.</em></p><p>بكتيريا &quot;النيسرية السحائية (نيسيريا مينينجيتيديس)&quot; من الأنواع A، وC، وW-135، وY يمكن أن تسبب أمراضًا خطيرة مثل:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب السحايا - عدوى تصيب النسيج الذي يبطن المخ والحبل الشوكي.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنتان الدموي - عدوى تصيب الدم.</p><p>تنتقل حالات العدوى هذه من شخص إلى آخر بسهولة ويمكن أن تسبب الوفاة إذا لم تُعالج.</p><p>يمكن إعطاء نيمنريكس للبالغين، والمراهقين، والأطفال، والرضّع الذين تزيد أعمارهم عن 6 أسابيع.</p><p>&nbsp;</p><p><strong>كيف يعمل نيمنريكس</strong></p><p>يساعد نيمنريكس جسمك على إنتاج عناصر الوقاية الطبيعية الخاصة به (الأجسام المضادة) من البكتيريا. وتساعد هذه الأجسام المضادة في وقايتك من الأمراض.</p><p>&nbsp;</p><p>سوف يقي نيمنريكس فقط من حالات العدوى التي تسببها بكتيريا &quot;النيسرية السحائية (نيسيريا مينينجيتيديس)&quot; من الأنواع A، وC، وW-135، وY.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استعمال نيمنريكس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عدم إعطائك نيمنريكس إذا كنت مصابًا بالحساسية تجاه المواد الفعالة أو أي من المكونات الأخرى في هذا اللقاح (المدرجة في القسم ٦).</p><p dir="RTL">علامات تفاعلات الحساسية قد تتضمن الطفح الجلدي المثير للحكة، وضيق التنفس، وتورم الوجه أو اللسان. <strong>اذهب لزيارة طبيبك فورًا إذا لاحظت أيًا من هذه العلامات</strong>.</p><p dir="RTL">إذا لم تكن متأكدًا مما ينبغي عليك فعله، فتحدث إلى طبيبك أو الممرضة قبل أن تتلقى نيمنريكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال نيمنريكس</strong></p><p dir="RTL">راجع طبيبك أو الممرضة قبل أن تتلقى هذا اللقاح إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بعدوى مصحوبة بارتفاع درجة الحرارة (أكبر من ٣٨ درجة مئوية). إذا كان هذا ينطبق عليك، فلن يتم إعطاء اللقاح حتى تتحسن حالتك. أما حالات العدوى البسيطة، كالبرد مثلًا، فهي لا تمثل مشكلة. بالرغم من ذلك، تحدث إلى طبيبك أو الممرضة أولًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلة تتعلق بالنزيف أو كنت تتكدم بسهولة.</p><p dir="RTL">إذا انطبق عليك أي من الحالات الواردة أعلاه (أو لم تكن متأكدًا مما ينبغي فعله)، فتحدث إلى طبيبك أو الممرضة قبل أن تتلقى نيمنريكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن ألا يوفر نيمنريكس الوقاية التامة لجميع من تلقّى اللقاح. إذا كان جهازك المناعي ضعيفًا (على سبيل المثال بسبب عدوى فيروس نقص المناعة البشرية (HIV) أو الأدوية التي تؤثر على جهاز المناعة)، فقد لا تستفيد من نيمنريكس بشكل كامل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يحدث الإغماء (غالبًا لدى المراهقين) بعد، أو حتى قبل، أي عملية حقن بالإبرة. لذا أخبر الطبيب أو الممرضة إذا تعرضت أنت أو طفلك للإغماء عند تلقّي حقنة سابقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الممرضة إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى، بما في ذلك اللقاحات والأدوية الأخرى التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يعمل نيمنريكس بنفس الكفاءة إذا كنت تتناول أدوية تؤثر على جهازك المناعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الرضع، يمكن إعطاء نيمنريكس بالتزامن مع لقاحات الدفتريا والتيتانوس والسعال الديكي اللا خلوي (DTaP) المركبة، بما في ذلك تركيبة لقاحات الدفتريا والتيتانوس والسعال الديكي اللا خلوي مع لقاح فيروس التهاب الكبد الوبائي B، أو فيروس شلل الأطفال المعطل، أو لقاح المستدمية النزلية (هيموفيلس إنفلونزا) من النوع b (HBV، أو IPV، أو Hib) مثل لقاح الدفتريا والتيتانوس والسعال الديكي اللا خلوي-فيروس التهاب الكبد الوبائي B-فيروس شلل الأطفال المعطَل/المستدمية النزلية (هيموفيلس إنفلونزا) من النوع b، واللقاح المتقارن عشاري التكافؤ للمكورات الرئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من عمر عام واحد فأكثر، يمكن إعطاء نيمنريكس بالتزامن مع أي من اللقاحات التالية: لقاحات التهاب الكبد الوبائي A (فيروس التهاب الكبد الوبائي A &rlm;(HAV)) والتهاب الكبد الوبائي B (فيروس التهاب الكبد الوبائي &rlm;B &rlm;(HBV))، أو لقاح الحصبة والنكاف والحصبة الألمانية (MMR)، أو لقاح الحصبة والنكاف والحصبة الألمانية والحماق (MMRV)، أو اللقاح المتقارن عشاري التكافؤ للمكورات الرئوية، أو لقاح الإنفلونزا الموسمية الذي لا يحتوي على مادة مساعدة&rlm;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في العام الثاني من العمر، يمكن إعطاء نيمنريكس أيضًا بالتزامن مع لقاحات الدفتريا والتيتانوس والسعال الديكي اللا خلوي (DTaP) المركبة، بما في ذلك تركيبة لقاحات الدفتريا والتيتانوس والسعال الديكي اللا خلوي مع لقاح فيروس التهاب الكبد الوبائي B، أو فيروس شلل الأطفال المعطَل، أو لقاح المستدمية النزلية (هيموفيلس إنفلونزا) من النوع b (HBV، أو IPV، أو Hib) مثل لقاح الدفتريا والتيتانوس والسعال الديكي اللا خلوي-فيروس التهاب الكبد الوبائي B-فيروس شلل الأطفال المعطَل/المستدمية النزلية (هيموفيلس إنفلونزا) من النوع b (DTaP-HBV-IPV/Hib)، واللقاح المتقارن للمكورات الرئوية ذي التكافؤ الثلاث عشري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة الأفراد الذين تتراوح أعمارهم من ٩ أعوام إلى ٢٥ عامًا، يمكن إعطاء نيمنريكس بالتزامن مع لقاح فيروس الورم الحليمي البشري [النوعان ١٦، ١٨] وأحد اللقاحات المركبة للدفتريا (محتوى المستضد منخفض)، والتيتانوس، والسعال الديكي اللا خلوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كلما أمكن، ينبغي استخدام نيمنريكس بالتزامن مع لقاح يحتوي على ذوفان التيتانوس (TT)، مثل لقاح الدفتريا والتيتانوس والسعال الديكي اللا خلوي-فيروس التهاب الكبد الوبائي B-فيروس شلل الأطفال المعطَل/المستدمية النزلية (هيموفيلس إنفلونزا) من النوع b، أو ينبغي إعطاء نيمنريكس قبل شهر واحد على الأقل من اللقاح الذي يحتوي على ذوفان التيتانوس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم استخدام موضع حقن مختلف لكل لقاح.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للحمل أو كنتِ تُرضعين رضاعة طبيعية، يجب أن تخبري طبيبكِ قبل تلقي نيمنريكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير نيمنريكس على القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر نيمنريكس على قدرتك على القيادة أو استخدام الآلات. بالرغم من ذلك، لا تقم بالقيادة أو استخدام أي آلات إذا كنت تشعر بالتوعك.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات نيمنريكس</strong></p><p dir="RTL"><strong>يحتوي نيمنريكس على الصوديوم</strong></p><p dir="RTL">يحتوي هذا اللقاح على أقل من ١ مليمول (٢٣ ملجم) من الصوديوم لكل جرعة، أي أنه &quot;خال من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيقوم طبيب أو ممرضة بإعطائك نيمنريكس.</p><p>يُحقن نيمنريكس دائمًا في إحدى العضلات، وعادةً ما تكون في أعلى الذراع أو الفخذ.</p><p>&nbsp;</p><p><em>التحصينات الأساسية</em></p><p><u>&nbsp;</u></p><p><u>الرضّع من عمر 6 أسابيع إلى أقل من 6 أشهر </u></p><p>حقنتان يتم إعطاؤهما بفارق شهرين، على سبيل المثال عند بلوغ شهرين وعند بلوغ 4 أشهر (يمكن إعطاء أول حقنة من عمر 6 أسابيع).</p><p>&nbsp;</p><p><u>الرضّع من عمر 6 أشهر والأطفال والمراهقون والبالغون</u></p><p>حقنة واحدة.</p><p>&nbsp;</p><p><em>الجرعات المنشطة</em></p><p><em>&nbsp;</em></p><p><u>الرضّع من عمر 6 أسابيع إلى أقل من 12 شهرًا:</u></p><p>جرعة منشطة واحدة في عمر 12 شهرًا، بعد آخر جرعة من نيمنريكس بشهرين على الأقل.</p><p>&nbsp;</p><p><u>الأشخاص بعمر 12 شهرًا أو أكبر الذين تم تحصينهم من قبل:</u></p><p>يُرجى إخبار طبيبك إذا كان قد تم إعطاؤك حقنة سابقة بلقاح آخر للمكورات السحائية بخلاف نيمنريكس.</p><p><em>&nbsp;</em></p><p>سيخبرك طبيبك ما إذا كنت تحتاج إلى جرعة إضافية من نيمنريكس أم لا وسيخبرك عندما تحتاج إليها، خاصة إذا:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلقيت أنت أو طفلك جرعتكما الأولى في عمر 6-14 شهرًا وقد تكونان عرضة بشكل خاص لخطر الإصابة بالعدوى التي تسببها بكتيريا النيسرية السحائية (نيسيريا مينينجيتيديس) من الأنواع W-135 وY</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلقيت أنت أو طفلك جرعتكما منذ أكثر من عام واحد تقريبًا وقد تكونان عرضة لخطر الإصابة بالعدوى التي تسببها بكتيريا النيسرية السحائية (نيسيريا مينينجيتيديس) من النوع A</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلقيت أنت أو طفلك جرعتكما الأولى في عمر 12-23 شهرًا وقد تكونان معرضان بشكل خاص لخطر الإصابة بالعدوى التي تسببها بكتيريا النيسرية السحائية (نيسيريا مينينجيتيديس) من الأنواع A، وC، وW-135، وY</p><p>&nbsp;</p><p>سيتم إبلاغك بالموعد الذي ينبغي أن تعود أنت أو طفلك فيه لتلقي الحقنة التالية. إذا فاتتك أنت أو طفلك حقنة محدد موعدها، فمن المهم أن تحدد موعدًا آخر.</p><p>&nbsp;</p><p>تأكد من أن تنهي أنت أو طفلك دورة التحصين (التطعيم) بالكامل.</p><p>&nbsp;</p><p>إذا كان لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع. قد تحدث الآثار الجانبية التالية عند استخدام هذا الدواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا (قد تحدث هذه الآثار مع أكثر من جرعة واحدة من كل ١٠ جرعات من اللقاح):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب (الإرهاق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتهيج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم موضع إعطاء الحقن واحمراره والشعور بألم فيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تحدث هذه الآثار مع ما يصل إلى جرعة واحدة من كل ١٠ جرعات من اللقاح):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التكدم (الورم الدموي) في موضع إعطاء الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات المعدة والهضم مثل الإسهال، والقيء، والغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي (لدى الرضّع).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تحدث هذه الآثار مع ما يصل إلى جرعة واحدة من كل ١٠٠ جرعة من اللقاح):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البكاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بألم في الذراعين أو الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور العام بالتوعك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشعور أو الحساسية، خاصة في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات في موضع إعطاء الحقن مثل الحكة، أو الشعور بالدفء أو الخدر، أو وجود كتلة صلبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تحدث هذه الآثار مع ما يصل إلى جرعة واحدة من كل ١٠٠٠ جرعة من اللقاح):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التشنجات (النوبات) المرتبطة بارتفاع درجة الحرارة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة:</strong> لا يمكن تقدير معدل التكرار من البيانات المتاحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم موضع الحقن واحمراره؛ قد يصيب هذا منطقة كبيرة من الطرف الذي تم حقن اللقاح فيه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم العقد الليمفاوية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي أعراض جانبية محتملة <strong><u>في المركز الوطني</u></strong> غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً <strong><u>للتيقظ والسلامة الدوائية</u></strong>. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المركز الوطني للتيقظ والسلامة الدوائية (NPC)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>مركز اتصال هيئة الغذاء والدواء السعودية (SFDA): ۱۹۹۹۹</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج الأخرى:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتخزينه في البراد (الثلاجة) (من درجتين مئويتين إلى 8 درجات مئوية).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتخزينه في العبوة الأصلية لحمايته من الضوء.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بتجميده.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد التحضير، تحتوي الجرعة الواحدة (٥, ٠ مل) على:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عديد السكاريد للنيسرية السحائية (نيسيريا مينينجيتيديس) من المجموعة A&rlm;<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥ ميكروجرامات</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عديد السكاريد للنيسرية السحائية (نيسيريا مينينجيتيديس) من المجموعة C&rlm;<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥ ميكروجرامات</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عديد السكاريد للنيسرية السحائية (نيسيريا مينينجيتيديس) من المجموعة W-135&rlm;<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥ ميكروجرامات</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عديد السكاريد للنيسرية السحائية (نيسيريا مينينجيتيديس) من المجموعة Y&rlm;<sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥ ميكروجرامات</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup>متقارن مع البروتين الحامل لذوفان التيتانوس&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٤٤&nbsp;ميكروجرامًا</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المسحوق: سكروز وتروميتامول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المذيب: كلوريد الصوديوم (انظر القسم ٢ &quot;يحتوي نيمنريكس على الصوديوم&quot; وماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>نيمنريكس هو مسحوق ومذيب لتحضير محلول مخصص للحقن. يتم توفير نيمنريكس في صورة مسحوق أبيض أو قطعة بيضاء في قارورة زجاجية ذات جرعة فردية، ومذيب صافٍ عديم اللون في محقنة مسبقة التعبئة. يجب خلط هذين الاثنين معًا قبل الاستخدام. سيظهر اللقاح المخلوط في صورة محلول صافٍ عديم اللون. يتوفر نيمنريكس في عبوات تحتوي على جرعة واحدة أو 10 جرعات مع الإبر أو بدونها. قد لا تُطرح جميع أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>مالك تصريح التسويق</strong></p><p dir="RTL">&nbsp;Pfizer Europe MA EEIG, Belgium&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة الصانعة</strong></p><p dir="RTL">&nbsp; Pfizer Manufacturing Belgium NV, Puurs, Belgium<br />&nbsp;</p></td></tr></tbody></table><p>-------------------------------------------------------------------------------------------------------------------------</p><p>المعلومات التالية موجهة لأخصائيي الرعاية الصحية فقط:</p><p><em>&nbsp;</em></p><p>اللقاح مخصص للاستخدام في العضل فقط. لا تحقنه في الأوعية الدموية، أو في الأدمة، أو تحت الجلد.</p><p>&nbsp;</p><p>إذا استُخدم نيمنريكس بالتزامن مع لقاحات أخرى، ينبغي استخدام مواضع حقن مختلفة.</p><p>&nbsp;</p><p>ينبغي عدم خلط نيمنريكس مع لقاحات أخرى.</p><p>&nbsp;</p><p><strong>تعليمات تحضير اللقاح بالمذيب المتوفر في المحقنة مسبقة التعبئة:</strong></p><p>&nbsp;</p><p>يجب تحضير نيمنريكس بإضافة محتوى المحقنة مسبقة التعبئة من المذيب بأكمله إلى القارورة التي تحتوي على المسحوق.</p><p>لتركيب الإبرة في المحقنة، انظر الصورة. ولكن قد تكون المحقنة المزوَدة مع نيمنريكس مختلفة قليلًا (دون حزّ لولبي) عن المحقنة الموصوفة في الصورة. في هذه الحالة، ينبغي تركيب الإبرة دون لفّها.</p><p>&nbsp;</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بينما تمسك <strong><u>أنبوب</u></strong> المحقنة في إحدى اليدين</p><p>(تجنب إمساك مكبس المحقنة)،</p><p>قم بفك غطاء المحقنة عن طريق لفه عكس اتجاه عقارب الساعة.</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>مكبس المحقنة</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>أنبوب المحقنة</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>غطاء المحقنة</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لتركيب الإبرة في المحقنة،</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بلف الإبرة باتجاه عقارب الساعة فوق المحقنة</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حتى تشعر أنها قد ثبتت (انظر الصورة).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزع واقي الإبرة، الذي قد يكون</p><p>مثبتًا بشدة في بعض الأحيان.</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>واقي الإبرة</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أضف المذيب إلى المسحوق. بعد إضافة المذيب إلى المسحوق، ينبغي رج الخليط جيدًا حتى يذوب المسحوق بشكل كامل في المذيب.</p><p>&nbsp;</p><p>اللقاح المحضَر يكون محلولًا صافيًا عديم اللون.</p><p>ينبغي فحص اللقاح المحضَر بالنظر للتأكد من عدم وجود أي جسيمات غريبة و/أو تغير في شكله قبل الحقن. في حالة ملاحظة أي من ذلك، تخلص من اللقاح.</p><p>ينبغي استخدام اللقاح بعد تحضيره على الفور.</p><p>&nbsp;</p><p>ينبغي استخدام إبرة جديدة لحقن اللقاح.</p><p>&nbsp;</p><p>ينبغي التخلص من أي منتج دوائي غير مستخدم أو من النفايات وفقًا للمتطلبات المحلية.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>إن هذا دواء</strong></p><p><strong>&nbsp;</strong></p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الدواء هو منتج يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر.</p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>اتبع بدقة وصفة الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي قام بصرف الدواء.</p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الطبيب والصيدلي خبيران في الأدوية وفوائدها ومخاطرها.</p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لا تقطع فترة العلاج الموصوفة لك من تلقاء نفسك.</p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لا تكرر صرف نفس الوصفة الطبية دون استشارة طبيبك.</p><p><strong>&nbsp;</strong></p><p><strong>احفظ جميع الأدوية بعيدًا عن متناول ومرأى الأطفال</strong></p><p><strong>&nbsp;</strong></p><p><strong>مجلس وزراء الصحة العرب</strong></p><p><strong>&nbsp;</strong></p><p><strong>اتحاد الصيادلة العرب</strong></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nimenrix powder and solvent for solution for injection in pre-filled syringe
Meningococcal groups A, C, W-135 and Y conjugate vaccine
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                After reconstitution, 1 dose (0.5 ml) contains:

Neisseria meningitidis group A polysaccharide1	5 micrograms
Neisseria meningitidis group C polysaccharide1	5 micrograms
Neisseria meningitidis group W-135 polysaccharide1	5 micrograms
Neisseria meningitidis group Y polysaccharide1	5 micrograms

1conjugated to tetanus toxoid carrier protein	44 micrograms

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection.
The powder or cake is white.
The solvent is clear and colourless.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by <em>Neisseria meningitidis</em> groups A, C, W-135, and Y.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>Nimenrix should be used in accordance with available official recommendations.</p><p>&nbsp;</p><p><em>Primary immunisation</em></p><p>Infants from 6 weeks to less than 6 months of age: two doses, each of 0.5 ml, should be administered with an interval of 2&nbsp;months between doses.</p><p>&nbsp;</p><p>Infants from 6 months of age, children, adolescents and adults: a single 0.5 mL dose should be administered.</p><p>An additional primary dose of Nimenrix may be considered appropriate for some individuals (see section 4.4).</p><p>&nbsp;</p><p><em>Booster doses</em></p><p>Long-term antibody persistence data following vaccination with Nimenrix are available up to 10 years after vaccination (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>After completion of the primary immunisation course in infants 6 weeks to less than 12 months of age, a booster dose should be given at 12 months of age with an interval of at least 2 months after the last Nimenrix vaccination (see section 5.1).</p><p>&nbsp;</p><p>In previously vaccinated individuals 12 months of age and older, Nimenrix may be given as a booster dose if they have received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Immunisation should be carried out by intramuscular injection only.</p><p>&nbsp;</p><p>In infants, the recommended injection site is the anterolateral aspect of the thigh. In individuals from 1&nbsp;year of age, the recommended injection site is the anterolateral aspect of the thigh or&nbsp;the deltoid muscle (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p><u>&nbsp;</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p>Nimenrix should under no circumstances be administered intravascularly, intradermally or subcutaneously.</p><p>&nbsp;</p><p>It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable effects) and a clinical examination.</p><p>&nbsp;</p><p>Appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.</p><p>&nbsp;</p><p><u>Intercurrent illness</u></p><p>&nbsp;</p><p>Vaccination with Nimenrix should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.</p><p>&nbsp;</p><p><u>Syncope</u></p><p>&nbsp;</p><p>Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during<em> </em>recovery. It is important that procedures are in place to avoid injury from faints.</p><p>&nbsp;</p><p><u>Thrombocytopenia and coagulation disorders</u></p><p>&nbsp;</p><p>Nimenrix should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.</p><p>&nbsp;</p><p><u>Immunodeficiency</u></p><p>&nbsp;</p><p>It may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate immune response may not be elicited.</p><p>&nbsp;</p><p>Persons with familial complement deficiencies (for example, C5 or C3 deficiencies) and persons receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by <em>Neisseria meningitidis</em> groups A, C, W-135 and Y, even if they develop antibodies following vaccination with Nimenrix.</p><p>&nbsp;</p><p><u>Protection against meningococcal disease</u></p><p>&nbsp;</p><p>Nimenrix will only confer protection against <em>Neisseria meningitidis</em> groups A, C, W-135 and Y. The vaccine will not protect against any other <em>Neisseria meningitidis</em> groups.</p><p>&nbsp;</p><p>A protective immune response may not be elicited in all vaccinees.</p><p>&nbsp;</p><p><em>Effect of prior vaccination with plain polysaccharide meningococcal vaccine</em></p><p>Subjects previously vaccinated with a plain polysaccharide meningococcal vaccine and vaccinated with Nimenrix 30 to 42 months later had lower Geometric Mean Titres (GMTs) measured with a serum bactericidal assay using rabbit complement (rSBA) than subjects who had not been vaccinated with any meningococcal vaccine in the preceding 10 years (see section 5.1). The clinical relevance of this observation is unknown.</p><p>&nbsp;</p><p><em>Effect of pre-vaccination antibody to tetanus toxoid</em></p><p>The safety and immunogenicity of Nimenrix was evaluated when it was sequentially administered or co-administered with a vaccine containing, diphtheria and tetanus toxoids, acellular pertussis, inactivated polioviruses (1, 2 and 3), hepatitis B surface antigen and <em>Haemophilus influenzae</em> type&nbsp;b polyribosyl ribose phosphate conjugated to tetanus toxoid (DTaP-HBV-IPV/Hib) in the second year of life. The administration of Nimenrix one month after the DTaP-HBV-IPV/Hib vaccine resulted in lower rSBA GMTs against groups A, C and W-135 compared with co-administration (see section 4.5). The clinical relevance of this observation is unknown.</p><p>&nbsp;</p><p><em>Immune response in infants aged 6 months to less than </em><em>12 months</em></p><p>A single dose administered at 6 months was associated with lower human complement serum bactericidal assay (hSBA) titres to groups W-135 and Y compared with three doses administered at 2, 4, and 6 months (see section 5.1). The clinical relevance of this observation is unknown. If an infant aged 6&nbsp;months to less than 12 months is expected to be at particular risk of invasive meningococcal disease due to exposure to groups W-135 and/or Y, consideration may be given to administering a second primary dose of Nimenrix after an interval of 2 months.</p><p>&nbsp;</p><p><em>Immune responses in toddlers aged 12-14 months</em></p><p>Toddlers aged 12-14 months had similar rSBA titres to groups A, C, W-135 and Y at one month after one dose of Nimenrix or at one month after two doses of Nimenrix given two months apart.</p><p>&nbsp;</p><p>A single dose was associated with lower hSBA titres to groups W-135 and Y compared with two doses given two months apart. Similar responses to groups A and C were observed after one or two doses (see section 5.1). The clinical relevance of this observation is unknown. If a toddler is expected to be at particular risk of invasive meningococcal disease due to exposure to groups W-135 and/or Y, consideration may be given to administering a second dose of Nimenrix after an interval of 2 months. Regarding waning of antibody against group A or group C after a first dose of Nimenrix in children aged 12-23 months, see under Persistence of serum bactericidal antibody titres.</p><p>&nbsp;</p><p><u>Persistence of serum bactericidal antibody titres</u></p><p><u>&nbsp;</u></p><p>Following administration of Nimenrix there is a waning of serum bactericidal antibody titres against group A when using hSBA (see section 5.1).&nbsp;The clinical relevance of this observation is unknown. However, if an individual is expected to be at particular risk of exposure to group A and received a dose of Nimenrix more than approximately one year previously, consideration may be given to administering a booster dose.</p><p>&nbsp;</p><p>A decline in antibody titres over time has been observed for groups A, C, W-135 and Y. The clinical relevance of this observation is unknown. A booster dose might be considered in individuals vaccinated at toddler age remaining at high risk of exposure to meningococcal disease caused by groups A, C, W‑135 or Y (see section 5.1).</p><p><em>&nbsp;</em></p><p><u>Effect of Nimenrix on anti-tetanus antibody concentrations</u></p><p><u>&nbsp;</u></p><p>Although an increase of the anti-tetanus toxoid (TT) antibody concentrations was observed following vaccination with Nimenrix, Nimenrix does not substitute for tetanus immunisation.</p><p>&nbsp;</p><p>Giving Nimenrix with or one month before a TT-containing vaccine in the second year of life does not impair the response to TT or significantly affect safety. No data are available beyond the age of 2&nbsp;years.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In infants, Nimenrix can be given concomitantly with combined DTaP-HBV-IPV/Hib vaccines and with 10-valent pneumococcal conjugate vaccine.</p><p>&nbsp;</p><p>From age 1 year and above, Nimenrix can be given concomitantly with any of the following vaccines: hepatitis A (HAV) and hepatitis B (HBV) vaccines, measles - mumps - rubella (MMR) vaccine, measles - mumps - rubella - varicella (MMRV) vaccine, 10-valent pneumococcal conjugate vaccine or unadjuvanted seasonal influenza vaccine.</p><p>&nbsp;</p><p>In the second year of life, Nimenrix can also be given concomitantly with combined diphtheria - tetanus - acellular pertussis (DTaP) vaccines, including combination DTaP vaccines with hepatitis B, inactivated poliovirus or <em>Haemophilus influenzae</em> type b (HBV, IPV or Hib) such as DTaP-HBV-IPV/Hib vaccine, and 13-valent pneumococcal conjugate vaccine.</p><p>&nbsp;</p><p>In individuals aged 9 to 25 years, Nimenrix can be given concomitantly with human papillomavirus bivalent [Type 16 and 18] vaccine, recombinant (HPV2).</p><p>&nbsp;</p><p>Whenever possible, Nimenrix and a TT containing vaccine, such as DTaP-HBV-IPV/Hib vaccine, should be co-administered or Nimenrix should be administered at least one month before the TT containing vaccine.</p><p>&nbsp;</p><p>One month after co-administration with a 10-valent pneumococcal conjugate vaccine, lower Geometric Mean antibody Concentrations (GMCs) and opsonophagocytic assay (OPA) antibody GMTs were observed for one pneumococcal serotype (18C conjugated to tetanus toxoid carrier protein). The clinical relevance of this observation is unknown. There was no impact of co-administration on immune responses to the other nine pneumococcal serotypes.</p><p>&nbsp;</p><p>One month after co-administration with a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Tdap) in subjects aged 9 to 25 years, lower GMCs were observed to each pertussis antigen (pertussis toxoid [PT], filamentous haemagglutinin [FHA] and pertactin [PRN]). More than 98% of subjects had anti-PT, FHA or PRN concentrations above the assay cut-off thresholds. The clinical relevance of these observations is unknown. There was no impact of co-administration on immune responses to Nimenrix or the tetanus or diphtheria antigens included in Tdap.</p><p>&nbsp;</p><p>If Nimenrix is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.</p><p>&nbsp;</p><p>It may be expected that in patients receiving immunosuppressive treatment, an adequate response may not be elicited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There is limited experience with use of Nimenrix in pregnant women.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development (see section 5.3).</p><p>&nbsp;</p><p>Nimenrix should be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether Nimenrix is excreted in human milk.</p><p>&nbsp;</p><p>Nimenrix should only be used during breast-feeding when the possible advantages outweigh the potential risks.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Nimenrix on the ability to drive and use machines have been performed.</p><p>However, some of the effects mentioned under section 4.8 &ldquo;Undesirable effects&rdquo; may affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety of Nimenrix presented in the table below is based on two clinical study datasets as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A pooled analysis of data from 9,621 subjects administered a single dose of Nimenrix. This total included 3,079 toddlers (12 months to 23 months), 909 children between 2 and 5 years of age, 990 children between 6 and 10 years of age, 2,317 adolescents (11 to 17 years) and 2,326 adults (18 to 55 years).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Data from a study in infants aged 6 to 12 weeks at the time of the first dose (Study MenACWY‑TT-083), 1,052 subjects received at least one dose of<strong> </strong>a primary series of 2 or 3 doses of Nimenrix and 1,008 received a booster dose at approximately 12 months of age.</p><p>&nbsp;</p><p>Safety data have also been evaluated in a separate study, in which a single dose of Nimenrix was administered to 274 individuals aged 56 years and older.</p><p>&nbsp;</p><p><em>Local and general adverse reactions</em></p><p>In the 6-12 weeks and in the 12-14 months age groups who received 2 doses of Nimenrix given 2&nbsp;months apart, the first and second doses were associated with similar local and systemic reactogenicity.</p><p>&nbsp;</p><p>The local and general adverse reaction profile of a booster dose of Nimenrix given to subjects from 12&nbsp;months through 30 years of age after primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccines, was similar to the local and general adverse reaction profile observed after primary vaccination with Nimenrix, except for gastrointestinal symptoms (including diarrhoea, vomiting, and nausea), which were very common among subjects 6 years of age and older.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions reported are listed according to the following frequency categories:</p><p>&nbsp;</p><p>Very common:&nbsp;&nbsp; (&ge;1/10)</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/100 to &lt;1/10)</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/1,000 to &lt;1/100)</p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&lt;1/10,000)</p><p>Not known (cannot be estimated from available data)</p><p>&nbsp;</p><p>Table 1 shows the adverse reactions reported from the studies in subjects aged from 6 weeks up to 55&nbsp;years of age and post-marketing experience. Adverse reactions reported in subjects aged &gt;55&nbsp;years were similar to those observed in younger adults.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 1:</strong> <strong>Tabulated summary of adverse reactions by system organ class</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Not known***</p></td><td style="vertical-align:top"><p>Lymphadenopathy</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Appetite lost</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Irritability</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Insomnia</p><p>Crying</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Drowsiness</p><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypoaesthesia</p><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Febrile convulsion</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Diarrhoea</p><p>Vomiting</p><p>Nausea*</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Urticaria</p><p>Rash**</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Myalgia</p><p>Pain in extremity</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fever</p><p>Swelling at injection site</p><p>Pain at injection site</p><p>Redness at injection site</p><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Injection site haematoma*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Malaise</p><p>Injection site induration</p><p>Injection site pruritus</p><p>Injection site warmth</p><p>Injection site anaesthesia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known***</p></td><td style="vertical-align:top"><p>Extensive limb swelling at the injection site, frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb</p></td></tr></tbody></table><p>*Nausea and Injection site haematoma occurred at a frequency of Uncommon in infants</p><p>**Rash occurred at a frequency of Common in infants</p><p>***ADR identified post-marketing</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p>To reports any side effect(s):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia: </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><ul><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: vaccines, meningococcal vaccines, ATC code: J07AH08</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Anti-capsular meningococcal antibodies protect against meningococcal disease via complement mediated bactericidal activity. Nimenrix induces the production of bactericidal antibodies against capsular polysaccharides of <em>Neisseria meningitidis</em> groups A, C, W-135 and Y when measured by assays using either rSBA or hSBA.</p><p>&nbsp;</p><p><u>Immunogenicity in infants</u></p><p><u>&nbsp;</u></p><p>In Study MenACWY-TT-083, the first dose was administered at 6 to 12 weeks of age, the second after an interval of 2 months, and a third (booster) dose administered at approximately 12&nbsp;months of age. DTaP-HBV-IPV/Hib and a 10-valent pneumococcal vaccine were co-administered. Nimenrix elicited rSBA and hSBA titres against the four meningococcal groups as shown in Table 2. The response against group C was non-inferior to the one elicited by licensed MenC-CRM and MenC-TT vaccines in terms of percentages with rSBA titres &ge;8 at 1 month after the second dose.</p><p>&nbsp;</p><p>Data from this study support the extrapolation of the immunogenicity data and posology to infants from 12 weeks to less than 6 months of age.</p><p><u>&nbsp;</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:637px"><tbody><tr><td colspan="9"><p><strong>Table 2:&nbsp; </strong><strong>rSBA and hSBA titres following two doses of Nimenrix (or MenC-CRM or MenC-TT) given 2 months apart with the first dose administered to</strong><strong> infants </strong><strong>6‑12&nbsp;weeks of age and following </strong><strong>a booster at 12 months of age (Study MenACWY-TT-083)</strong></p></td></tr><tr><td rowspan="3"><p><strong>Meningo-coccal</strong></p><p><strong>group</strong></p></td><td rowspan="3"><p><strong>Vaccine group</strong></p></td><td rowspan="3"><p><strong>Time point</strong></p></td><td colspan="3"><p><strong>rSBA*</strong></p></td><td colspan="3"><p><strong>hSBA**</strong></p></td></tr><tr><td rowspan="2"><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p></td><td><p><strong>GMT</strong></p></td><td rowspan="2"><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p></td><td><p><strong>GMT</strong></p></td></tr><tr><td><p><strong>(95% CI)</strong></p></td><td><p><strong>(95% CI)</strong></p></td><td><p><strong>(95% CI)</strong></p></td><td><p><strong>(95% CI)</strong></p></td></tr><tr><td rowspan="2"><p><strong>A</strong></p></td><td rowspan="2"><p><strong>Nimenrix</strong></p></td><td><p>Post-dose 2<sup>(1)</sup></p></td><td><p>456</p></td><td><p>97.4%</p><p>(95.4; 98.6)</p></td><td><p>203</p><p>(182; 227)</p></td><td><p>202</p></td><td><p>96.5%</p><p>(93.0; 98.6)</p></td><td><p>157</p><p>(131; 188)</p></td></tr><tr><td><p>Post-booster<sup>(1)</sup></p></td><td><p>462</p></td><td><p>99.6%</p><p>(98.4; 99.9)</p></td><td><p>1561</p><p>(1412; 1725)</p></td><td><p>214</p></td><td><p>99.5% (97.4;100)</p></td><td><p>1007 (836;1214)</p></td></tr><tr><td rowspan="6"><p><strong>C</strong></p></td><td rowspan="2"><p><strong>Nimenrix</strong></p></td><td><p>Post-dose 2<sup>(1)</sup></p></td><td><p>456</p></td><td><p>98.7%</p><p>(97.2; 99.5)</p></td><td><p>612</p><p>(540; 693)</p></td><td><p>218</p></td><td><p>98.6%</p><p>(96.0; 99.7)</p></td><td><p>1308</p><p>(1052; 1627)</p></td></tr><tr><td><p>Post-booster<sup>(1)</sup></p></td><td><p>463</p></td><td><p>99.8%</p><p>(98.8; 100)</p></td><td><p>1177</p><p>(1059; 1308)</p></td><td><p>221</p></td><td><p>99.5%</p><p>(97.5; 100)</p></td><td><p>4992</p><p>(4086; 6100)</p></td></tr><tr><td rowspan="2"><p><strong>MenC-CRM vaccine</strong></p></td><td><p>Post-dose 2<sup>(1)</sup></p></td><td><p>455</p></td><td><p>99.6%</p><p>(98.4; 99.9)</p></td><td><p>958</p><p>(850; 1079)</p></td><td><p>202</p></td><td><p>100%</p><p>(98.2; 100)</p></td><td><p>3188</p><p>(2646; 3841)</p></td></tr><tr><td><p>Post-booster<sup>(1)</sup></p></td><td><p>446</p></td><td><p>98.4%</p><p>(96.8; 99.4)</p></td><td><p>1051</p><p>(920; 1202)</p></td><td><p>216</p></td><td><p>100%</p><p>(98.3; 100)</p></td><td><p>5438</p><p>(4412; 6702)</p></td></tr><tr><td rowspan="2"><p><strong>MenC-TT vaccine</strong></p></td><td><p>Post-dose 2<sup>(1)</sup></p></td><td><p>457</p></td><td><p>100%</p><p>(99.2; 100)</p></td><td><p>1188</p><p>(1080; 1307)</p></td><td><p>226</p></td><td><p>100%</p><p>(98.4; 100)</p></td><td><p>2626</p><p>(2219; 3109)</p></td></tr><tr><td><p>Post-booster<sup>(1)</sup></p></td><td><p>459</p></td><td><p>100%</p><p>(99.2; 100)</p></td><td><p>1960</p><p>(1776; 2163)</p></td><td><p>219</p></td><td><p>100%</p><p>(98.3; 100)</p></td><td><p>5542</p><p>(4765; 6446)</p></td></tr><tr><td rowspan="2"><p><strong>W</strong></p></td><td rowspan="2"><p><strong>Nimenrix</strong></p></td><td><p>Post-dose 2<sup>(1)</sup></p></td><td><p>455</p></td><td><p>99.1%</p><p>(97.8; 99.8)</p></td><td><p>1605</p><p>(1383; 1862)</p></td><td><p>217</p></td><td><p>100%</p><p>(98.3; 100)</p></td><td><p>753</p><p>(644; 882)</p></td></tr><tr><td><p>Post-booster<sup>(1)</sup></p></td><td><p>462</p></td><td><p>99.8%</p><p>(98.8; 100)</p></td><td><p>2777</p><p>(2485; 3104)</p></td><td><p>218</p></td><td><p>100%</p><p>(98.3; 100)</p></td><td><p>5123</p><p>(4504; 5826)</p></td></tr><tr><td rowspan="2"><p><strong>Y</strong></p></td><td rowspan="2"><p><strong>Nimenrix</strong></p></td><td><p>Post-dose 2<sup>(1)</sup></p></td><td><p>456</p></td><td><p>98.2%</p><p>(96.6; 99.2)</p></td><td><p>483</p><p>(419; 558)</p></td><td><p>214</p></td><td><p>97.7%</p><p>(94.6; 99.2)</p></td><td><p>328</p><p>(276; 390)</p></td></tr><tr><td><p>Post-booster<sup>(1)</sup></p></td><td><p>462</p></td><td><p>99.4%</p><p>(99.1; 99.9)</p></td><td><p>881</p><p>(787; 986)</p></td><td><p>217</p></td><td><p>100%</p><p>(98.3; 100)</p></td><td><p>2954</p><p>(2498; 3493)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the primary according-to-protocol (ATP) cohort.</p><table border="0" cellspacing="0" cellpadding="0" style="width:637px"><tbody><tr><td><p>*rSBA analysis performed at Public Health England (PHE) laboratories in UK</p><p>**hSBA analysis performed at GSK laboratories</p><p><sup>(1) </sup>blood sampling performed 21 to 48 days post vaccination</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>In Study MenACWY-TT-087, infants received either a single primary dose at 6 months followed by a booster dose at 15-18 months (DTaP-IPV/Hib and 10-valent pneumococcal conjugate vaccine was co‑administered at both vaccination time points) or three primary doses at 2, 4, and 6 months followed by a booster dose at 15-18 months. A single primary dose administered at 6 months of age elicited robust rSBA titres to the four meningococcal groups, as measured by the percentage of subjects with rSBA titres &ge;8, that were comparable to responses after the last dose of a three-dose primary series. A booster dose produced robust responses, comparable between the two dosing groups, against all four meningococcal groups. Results are shown in Table 3.</p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:625px"><thead><tr><td colspan="8"><p><strong>Table 3: rSBA and hSBA titres following a single dose of Nimenrix in infants at 6&nbsp;months of age and pre-and post-booster at 15-18 months of age (Study MenACWY-TT-087)</strong></p></td></tr><tr><td rowspan="2"><p><strong>Meningo-coccal</strong></p><p><strong>group</strong></p></td><td rowspan="2"><p><strong>Time point</strong></p></td><td colspan="3"><p><strong>rSBA*</strong></p></td><td colspan="3"><p><strong>hSBA**</strong></p></td></tr></thead><tbody><tr><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td rowspan="3"><p><strong>A</strong></p></td><td><p>Post-dose 1<sup>(1)</sup></p></td><td><p>163</p></td><td><p>98.8%</p><p>(95.6; 99.9)</p></td><td><p>1333</p><p>(1035; 1716)</p></td><td><p>59</p></td><td><p>98.3%</p><p>(90.9; 100)</p></td><td><p>271</p><p>(206; 355)</p></td></tr><tr><td><p>Pre-booster</p></td><td><p>131</p></td><td><p>81.7%</p><p>(74; 87.9)</p></td><td><p>125</p><p>(84.4; 186)</p></td><td><p>71</p></td><td><p>66.2%</p><p>(54; 77)</p></td><td><p>20.8<br />(13.5; 32.2)</p></td></tr><tr><td><p>Post-booster<sup>(1)</sup></p></td><td><p>139</p></td><td><p>99.3%</p><p>(96.1; 100)</p></td><td><p>2762</p><p>(2310; 3303)</p></td><td><p>83</p></td><td><p>100%</p><p>(95.7; 100)</p></td><td><p>1416<br />(1140; 1758)</p></td></tr><tr><td rowspan="3"><p><strong>C</strong></p></td><td><p>Post-dose 1<sup>(1)</sup></p></td><td><p>163</p></td><td><p>99.4%</p><p>(96.6; 100)</p></td><td><p>592</p><p>(482; 726)</p></td><td><p>66</p></td><td><p>100%</p><p>(94.6;100)</p></td><td><p>523</p><p>(382; 717)</p></td></tr><tr><td><p>Pre-booster</p></td><td><p>131</p></td><td><p>65.6%</p><p>(56.9; 73.7)</p></td><td><p>27.4</p><p>(20.6; 36.6)</p></td><td><p>78</p></td><td><p>96.2%</p><p>(89.2; 99.2)</p></td><td><p>151</p><p>(109; 210)</p></td></tr><tr><td><p>Post-booster<sup>(1)</sup></p></td><td><p>139</p></td><td><p>99.3%</p><p>(96.1; 100)</p></td><td><p>2525</p><p>(2102; 3033)</p></td><td><p>92</p></td><td><p>100%</p><p>(96.1; 100)</p></td><td><p>13360</p><p>(10953; 16296)</p></td></tr><tr><td rowspan="3"><p><strong>W</strong></p></td><td><p>Post-dose 1<sup>(1)</sup></p></td><td><p>163</p></td><td><p>93.9%</p><p>(89; 97)</p></td><td><p>1256</p><p>(917; 1720)</p></td><td><p>47</p></td><td><p>87.2%</p><p>(74.3; 95.2)</p></td><td><p>137</p><p>(78.4; 238)</p></td></tr><tr><td><p>Pre-booster</p></td><td><p>131</p></td><td><p>77.9%</p><p>(69.8; 84.6)</p></td><td><p>63.3</p><p>(45.6; 87.9)</p></td><td><p>53</p></td><td><p>100%</p><p>(93.3; 100)</p></td><td><p>429</p><p>(328; 559)</p></td></tr><tr><td><p>Post-booster<sup>(1)</sup></p></td><td><p>139</p></td><td><p>100%</p><p>(97.4; 100)</p></td><td><p>3145</p><p>(2637; 3750)</p></td><td><p>59</p></td><td><p>100%</p><p>(93.9; 100)</p></td><td><p>9016</p><p>(7045; 11537)</p></td></tr><tr><td rowspan="3"><p><strong>Y</strong></p></td><td><p>Post-dose 1<sup>(1)</sup></p></td><td><p>163</p></td><td><p>98.8%</p><p>(95.6; 99.9)</p></td><td><p>1470</p><p>(1187; 1821)</p></td><td><p>52</p></td><td><p>92.3%</p><p>(81.5; 97.9)</p></td><td><p>195</p><p>(118; 323)</p></td></tr><tr><td><p>Pre-booster</p></td><td><p>131</p></td><td><p>88.5%</p><p>(81.8; 93.4)</p></td><td><p>106</p><p>(76.4; 148)</p></td><td><p>61</p></td><td><p>98.4%</p><p>(91.2; 100)</p></td><td><p>389</p><p>(292; 518)</p></td></tr><tr><td><p>Post-booster<sup>(1)</sup></p></td><td><p>139</p></td><td><p>100%</p><p>(97.4; 100)</p></td><td><p>2749</p><p>(2301; 3283)</p></td><td><p>69</p></td><td><p>100%</p><p>(94.8; 100)</p></td><td><p>5978</p><p>(4747; 7528)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the primary ATP cohort.</p><p>*rSBA analysis performed at PHE laboratories in UK</p><p>**hSBA analysis performed at Neomed in Canada</p><p><sup>(1) </sup>blood sampling performed 1 month post vaccination</p><p><u>&nbsp;</u></p><p>Measurement of hSBA titres was a secondary endpoint in Study MenACWY-TT-087. Although similar responses to groups A and C were observed with both dosing schedules, a single primary dose in infants at 6 months was associated with lower hSBA titres to groups W-135 and Y as measured by the percentage of subjects with hSBA titres &ge;8 [87.2% (95% CI: 74.3, 95.2) and 92.3% (95% CI: 81.5, 97.9), respectively] compared with three primary doses at 2, 4, and 6 months of age [100% (95% CI: 96.6, 100) and 100% (95% CI: 97.1, 100),<em> </em>respectively] (see section 4.4). After a booster dose, hSBA titres to all four meningococcal groups were comparable between the two dosing schedules. Results are shown in Table 3.</p><p><u>&nbsp;</u></p><p><u>Immunogenicity in toddlers aged 12-23 months</u></p><p>&nbsp;</p><p>In clinical studies MenACWY-TT-039 and MenACWY-TT-040, a single dose of Nimenrix elicited SBA titres against the four meningococcal groups, with group C rSBA titres that were comparable to those elicited by a licensed MenC-CRM vaccine in terms of the percentage of subjects with rSBA titres &ge;8. In Study MenACWY-TT-039, hSBA was also measured as a secondary endpoint. Results are shown in Table 4.</p><p>&nbsp;</p><p><strong>Table 4:&nbsp; SBA* titres following a single dose of Nimenrix (or MenC-CRM) in toddlers aged 12‑23 months (Studies MenACWY-TT-039/040)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:702px"><tbody><tr><td rowspan="3"><p><strong>Meningo-coccal</strong></p><p><strong>group</strong></p></td><td rowspan="3"><p><strong>Vaccine group</strong></p></td><td colspan="6"><p><strong>Study MenACWY-TT-039</strong><strong><sup>(1)</sup></strong></p></td><td colspan="3"><p><strong>Study MenACWY-TT-040</strong><strong><sup>(2)</sup></strong></p></td></tr><tr><td colspan="3"><p><strong>rSBA* </strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>hSBA*</strong></p></td><td colspan="3"><p><strong>rSBA*</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td><p><strong>A</strong></p></td><td><p><strong>Nimenrix</strong></p></td><td><p>354</p></td><td><p>99.7%</p><p>(98.4; 100)</p></td><td><p>2205</p><p>(2008; 2422)</p></td><td><p>338</p></td><td><p>77.2%</p><p>(72.4; 81.6)</p></td><td><p>19.0</p><p>(16.4; 22.1)</p></td><td><p>183</p></td><td><p>98.4%</p><p>(95.3; 99.7)</p></td><td><p>3170</p><p>(2577; 3899)</p></td></tr><tr><td rowspan="2"><p><strong>C</strong></p></td><td><p><strong>Nimenrix</strong></p></td><td><p>354</p></td><td><p>99.7%</p><p>(98.4; 100)</p></td><td><p>478</p><p>(437; 522)</p></td><td><p>341</p></td><td><p>98.5%</p><p>(96.6; 99.5)</p></td><td><p>196</p><p>(175; 219)</p></td><td><p>183</p></td><td><p>97.3%</p><p>(93.7; 99.1)</p></td><td><p>829</p><p>(672; 1021)</p></td></tr><tr><td><p><strong>MenC-CRM vaccine</strong></p></td><td><p>121</p></td><td><p>97.5%</p><p>(92.9; 99.5)</p></td><td><p>212</p><p>(170; 265)</p></td><td><p>116</p></td><td><p>81.9%</p><p>(73.7; 88.4)</p></td><td><p>40.3</p><p>(29.5; 55.1)</p></td><td><p>114</p></td><td><p>98.2%</p><p>(93.8; 99.8)</p></td><td><p>691</p><p>(521; 918)</p></td></tr><tr><td><p><strong>W-135</strong></p></td><td><p><strong>Nimenrix</strong></p></td><td><p>354</p></td><td><p>100%</p><p>(99.0; 100)</p></td><td><p>2682</p><p>(2453; 2932)</p></td><td><p>336</p></td><td><p>87.5%</p><p>(83.5&nbsp;; 90.8)</p></td><td><p>48.9</p><p>(41.2; 58.0)</p></td><td><p>186</p></td><td><p>98.4%</p><p>(95.4; 99.7)</p></td><td><p>4022</p><p>(3269; 4949)</p></td></tr><tr><td><p><strong>Y</strong></p></td><td><p><strong>Nimenrix</strong></p></td><td><p>354</p></td><td><p>100%</p><p>(99.0; 100)</p></td><td><p>2729</p><p>(2473; 3013)</p></td><td><p>329</p></td><td><p>79.3%</p><p>(74.5; 83.6)</p></td><td><p>30.9</p><p>(25.8; 37.1)</p></td><td><p>185</p></td><td><p>97.3%</p><p>(93.8; 99.1)</p></td><td><p>3168</p><p>(2522; 3979)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohorts.</p><p><sup>(1) </sup>blood sampling performed 42 to 56 days post vaccination</p><p><sup>(2)</sup> blood sampling performed 30 to 42 days post vaccination</p><p>*SBA analyses performed at GSK laboratories</p><p>&nbsp;</p><p><em>Long-term immunogenicity in toddlers</em></p><p>Study MenACWY-TT-104 evaluated the immunogenicity after 1 month and the persistence of the response up to 5 years following 1 or 2 doses (given 2 months apart) of Nimenrix in toddlers aged 12&nbsp;to 14 months. One month following one or two doses Nimenrix elicited rSBA titres against all four meningococcal groups that were similar in terms of the percentage of subjects with rSBA titre &ge;8 and GMT.</p><p>&nbsp;</p><p>&nbsp;As a secondary endpoint hSBA titres were measured. One month post dose one or two Nimenrix elicited hSBA titres against groups W-135 and Y that were higher in terms of the percentage of subjects with hSBA titre &ge;8 when two doses were given compared with one (see section 4.4). Nimenrix elicited hSBA titres against groups A and C that were similar in terms of the percentage of subjects with hSBA titre &ge;8 when two doses were given compared with one. At Year 5 only a small difference in antibody persistence between one and two doses was observed, in terms of percentages of subjects with hSBA titres &ge;8 against all groups. Antibody persistence was observed at Year 5 against groups C, W-135 and Y. After one and two doses the percentages of subjects with hSBA titres &ge;8 for group C were 60.7% and 67.8%, group W-135 were 58.9% and 63.6% and group Y were 61.5% and 54.2%, respectively. For group A, 27.9% and 17.9% of subjects receiving one or two doses, respectively, had hSBA titres &ge;8. Results are shown in Table 5.</p><p>&nbsp;</p><p><strong>Table 5:&nbsp; rSBA and hSBA titres following one or two doses of Nimenrix with the first dose administered to toddlers aged 12-14 months</strong> <strong>and persistence up to 5 years (Study MenACWY-TT-104)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:672px"><thead><tr><td rowspan="2"><p><strong>Meningo-<br />coccal group</strong></p></td><td rowspan="2"><p><strong>Nimenrix<br />dose group</strong></p></td><td rowspan="2"><p><strong>Time point</strong><strong><sup>(1)</sup></strong></p></td><td colspan="3"><p><strong>rSBA*</strong></p></td><td colspan="3"><p><strong>hSBA**</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td rowspan="9"><p><strong>A</strong></p></td><td rowspan="4"><p><strong>1 dose</strong></p></td><td><p>Post dose 1</p></td><td><p>180</p></td><td><p>97.8%</p><p>(94.4; 99.4)</p></td><td><p>1437</p><p>(1118; 1847)</p></td><td><p>74</p></td><td><p>95.9%</p><p>(88.6; 99.2)</p></td><td><p>118</p><p>(86.8; 161)</p></td></tr><tr><td><p>Year 1</p></td><td><p>167</p></td><td><p>63.5%</p><p>(55.7; 70.8)</p></td><td><p>62.7</p><p>(42.6; 92.2)</p></td><td><p>70</p></td><td><p>35.1%</p><p>(25.9; 49.5)</p></td><td><p>6.1</p><p>(4.1; 8.9)</p></td></tr><tr><td><p>Year 3</p></td><td><p>147</p></td><td><p>46.9%</p><p>(38.7; 55.3)</p></td><td><p>29.7</p><p>(19.8; 44.5)</p></td><td><p>55</p></td><td><p>36.4%</p><p>(23.8; 50.4)</p></td><td><p>5.8</p><p>(3.8; 8.9)</p></td></tr><tr><td><p>Year 5</p></td><td><p>133</p></td><td><p>58.6%</p><p>(49.8; 67.1)</p></td><td><p>46.8</p><p>(30.7; 71.5)</p></td><td><p>61</p></td><td><p>27.9%</p><p>(17.1; 40.8)</p></td><td><p>4.4</p><p>(3.1; 6.2)</p></td></tr><tr><td rowspan="5"><p><strong>2 doses</strong></p></td><td><p>Post dose 1</p></td><td><p>158</p></td><td><p>96.8%</p><p>(92.8; 99.0)</p></td><td><p>1275</p><p>(970; 1675)</p></td><td><p>66</p></td><td><p>97.0%</p><p>(89.5; 99.6)</p></td><td><p>133</p><p>(98.1; 180)</p></td></tr><tr><td><p>Post dose 2</p></td><td><p>150</p></td><td><p>98.0%</p><p>(94.3; 99.6)</p></td><td><p>1176</p><p>(922; 1501)</p></td><td><p>66</p></td><td><p>97.0%</p><p>(89.5; 99.6)</p></td><td><p>170</p><p>(126; 230)</p></td></tr><tr><td><p>Year 1</p></td><td><p>143</p></td><td><p>70.6%</p><p>(62.4; 77.9)</p></td><td><p>76.6</p><p>(50.7; 115.7)</p></td><td><p>62</p></td><td><p>35.5%</p><p>(23.7; 48.7)</p></td><td><p>6.4</p><p>(4.2; 10.0)</p></td></tr><tr><td><p>Year 3</p></td><td><p>121</p></td><td><p>54.5%</p><p>(45.2; 63.6)</p></td><td><p>28.5</p><p>(18.7; 43.6)</p></td><td><p>50</p></td><td><p>36.0%</p><p>(22.9; 50.8)</p></td><td><p>5.4</p><p>(3.6; 8.0)</p></td></tr><tr><td><p>Year 5</p></td><td><p>117</p></td><td><p>65.8%</p><p>(56.5; 74.3)</p></td><td><p>69.9</p><p>(44.7; 109.3)</p></td><td><p>56</p></td><td><p>17.9%</p><p>(8.9; 30.4)</p></td><td><p>3.1</p><p>(2.4; 4.0)</p></td></tr><tr><td rowspan="9"><p><strong>C</strong></p></td><td rowspan="4"><p><strong>1 dose</strong></p></td><td><p>Post dose 1</p></td><td><p>179</p></td><td><p>95.0%</p><p>(90.7; 97.7)</p></td><td><p>452</p><p>(346; 592)</p></td><td><p>78</p></td><td><p>98.7%</p><p>(93.1; 100)</p></td><td><p>152</p><p>(105; 220)</p></td></tr><tr><td><p>Year 1</p></td><td><p>167</p></td><td><p>49.1%</p><p>(41.3; 56.9)</p></td><td><p>16.2</p><p>(12.4; 21.1)</p></td><td><p>71</p></td><td><p>81.7%</p><p>(70.7; 89.9)</p></td><td><p>35.2</p><p>(22.5; 55.2)</p></td></tr><tr><td><p>Year 3</p></td><td><p>147</p></td><td><p>35.4%</p><p>(27.7; 43.7)</p></td><td><p>9.8</p><p>(7.6; 12.7)</p></td><td><p>61</p></td><td><p>65.6%</p><p>(52.3; 77.3)</p></td><td><p>23.6</p><p>(13.9; 40.2)</p></td></tr><tr><td><p>Year 5</p></td><td><p>132</p></td><td><p>20.5%</p><p>(13.9; 28.3)</p></td><td><p>6.6</p><p>(5.3; 8.2)</p></td><td><p>61</p></td><td><p>60.7%</p><p>(47.3; 72.9)</p></td><td><p>18.1</p><p>(10.9; 30.0)</p></td></tr><tr><td rowspan="5"><p><strong>2 doses</strong></p></td><td><p>Post dose 1</p></td><td><p>157</p></td><td><p>95.5%</p><p>(91.0; 98.2)</p></td><td><p>369</p><p>(281; 485)</p></td><td><p>70</p></td><td><p>95.7%</p><p>(88.0; 99.1)</p></td><td><p>161</p><p>(110; 236)</p></td></tr><tr><td><p>Post dose 2</p></td><td><p>150</p></td><td><p>98.7%</p><p>(95.3; 99.8)</p></td><td><p>639</p><p>(522; 783)</p></td><td><p>69</p></td><td><p>100%</p><p>(94.8; 100)</p></td><td><p>1753</p><p>(1278; 2404)</p></td></tr><tr><td><p>Year 1</p></td><td><p>143</p></td><td><p>55.2%</p><p>(46.7; 63.6)</p></td><td><p>21.2</p><p>(15.6; 28.9)</p></td><td><p>63</p></td><td><p>93.7%</p><p>(84.5; 98.2)</p></td><td><p>73.4</p><p>(47.5; 113.4)</p></td></tr><tr><td><p>Year 3</p></td><td><p>121</p></td><td><p>33.9%</p><p>(25.5; 43.0)</p></td><td><p>11.5</p><p>(8.4; 15.8)</p></td><td><p>56</p></td><td><p>67.9%</p><p>(54.0; 79.7)</p></td><td><p>27.0</p><p>(15.6; 46.8)</p></td></tr><tr><td><p>Year 5</p></td><td><p>116</p></td><td><p>28.4%</p><p>(20.5; 37.6)</p></td><td><p>8.5</p><p>(6.4; 11.2)</p></td><td><p>59</p></td><td><p>67.8%</p><p>(54.4; 79.4)</p></td><td><p>29.4</p><p>(16.3; 52.9)</p></td></tr><tr><td rowspan="9"><p><strong>W-135</strong></p></td><td rowspan="4"><p><strong>1 dose</strong></p></td><td><p>Post dose 1</p></td><td><p>180</p></td><td><p>95.0%</p><p>(90.8; 97.7)</p></td><td><p>2120</p><p>(1601; 2808)</p></td><td><p>72</p></td><td><p>62.5%</p><p>(50.3; 73.6)</p></td><td><p>27.5</p><p>(16.1; 46.8)</p></td></tr><tr><td><p>Year 1</p><p>&nbsp;</p></td><td><p>167</p></td><td><p>65.3%</p><p>(57.5; 72.5)</p></td><td><p>57.2</p><p>(39.9; 82.0)</p></td><td><p>72</p></td><td><p>95.8%</p><p>(88.3; 99.1)</p></td><td><p>209.0</p><p>(149.9; 291.4)</p></td></tr><tr><td><p>Year 3</p></td><td><p>147</p></td><td><p>59.2%</p><p>(50.8; 67.2)</p></td><td><p>42.5</p><p>(29.2; 61.8)</p></td><td><p>67</p></td><td><p>71.6%</p><p>(59.3; 82.0)</p></td><td><p>30.5</p><p>(18.7; 49.6)</p></td></tr><tr><td><p>Year 5</p></td><td><p>133</p></td><td><p>44.4%</p><p>(35.8; 53.2)</p></td><td><p>25.0</p><p>(16.7; 37.6)</p></td><td><p>56</p></td><td><p>58.9%</p><p>(45.0; 71.9)</p></td><td><p>20.8</p><p>(11.6; 37.1)</p></td></tr><tr><td rowspan="5"><p><strong>2 doses</strong></p></td><td><p>Post dose 1</p></td><td><p>158</p></td><td><p>94.9%</p><p>(90.3; 97.8)</p></td><td><p>2030</p><p>(1511; 2728)</p></td><td><p>61</p></td><td><p>68.9%</p><p>(55.7; 80.1)</p></td><td><p>26.2</p><p>(16.0; 43.0)</p></td></tr><tr><td><p>Post dose 2</p></td><td><p>150</p></td><td><p>100%</p><p>(97.6; 100)</p></td><td><p>3533</p><p>(2914; 4283)</p></td><td><p>70</p></td><td><p>97.1%</p><p>(90.1; 99.7)</p></td><td><p>757</p><p>(550; 1041)</p></td></tr><tr><td><p>Year 1</p></td><td><p>143</p></td><td><p>77.6%</p><p>(69.9; 84.2)</p></td><td><p>123</p><p>(82.7; 183)</p></td><td><p>65</p></td><td><p>98.5%</p><p>(91.7; 100.0)</p></td><td><p>232.6</p><p>(168.3; 321.4)</p></td></tr><tr><td><p>Year 3</p></td><td><p>121</p></td><td><p>72.7%</p><p>(63.9; 80.4)</p></td><td><p>92.9</p><p>(59.9; 144)</p></td><td><p>54</p></td><td><p>87.0%</p><p>(75.1; 94.6)</p></td><td><p>55.5</p><p>(35.3; 87.1)</p></td></tr><tr><td><p>Year 5</p></td><td><p>117</p></td><td><p>50.4%</p><p>(41.0; 59.8)</p></td><td><p>37.1</p><p>(23.3; 59.0)</p></td><td><p>44</p></td><td><p>63.6%</p><p>(47.8; 77.6)</p></td><td><p>19.5</p><p>(10.7; 35.2)</p></td></tr><tr><td rowspan="9"><p><strong>Y</strong></p></td><td rowspan="4"><p><strong>1 dose</strong></p></td><td><p>Post dose 1</p></td><td><p>180</p></td><td><p>92.8%</p><p>(88.0; 96.1)</p></td><td><p>952</p><p>(705; 1285)</p></td><td><p>71</p></td><td><p>67.6%</p><p>(55.5; 78.2)</p></td><td><p>41.2</p><p>(23.7; 71.5)</p></td></tr><tr><td><p>Year 1</p></td><td><p>167</p></td><td><p>73.1%</p><p>(65.7; 79.6)</p></td><td><p>76.8</p><p>(54.2; 109.0)</p></td><td><p>62</p></td><td><p>91.9%</p><p>(82.2; 97.3)</p></td><td><p>144</p><p>(97.2; 214.5)</p></td></tr><tr><td><p>Year 3</p></td><td><p>147</p></td><td><p>61.9%</p><p>(53.5; 69.8)</p></td><td><p>58.0</p><p>(39.1; 86.0)</p></td><td><p>64</p></td><td><p>53.1%</p><p>(40.2; 65.7)</p></td><td><p>17.3</p><p>(10.1; 29.6)</p></td></tr><tr><td><p>Year 5</p></td><td><p>133</p></td><td><p>47.4%</p><p>(38.7; 56.2)</p></td><td><p>36.5</p><p>(23.6; 56.2)</p></td><td><p>65</p></td><td><p>61.5%</p><p>(48.6; 73.3)</p></td><td><p>24.3</p><p>(14.3; 41.1)</p></td></tr><tr><td rowspan="5"><p><strong>2 doses</strong></p></td><td><p>Post dose 1</p></td><td><p>157</p></td><td><p>93.6%</p><p>(88.6; 96.9)</p></td><td><p>933</p><p>(692; 1258)</p></td><td><p>56</p></td><td><p>64.3%</p><p>(50.4; 76.6)</p></td><td><p>31.9</p><p>(17.6; 57.9)</p></td></tr><tr><td><p>Post dose 2</p></td><td><p>150</p></td><td><p>99.3%</p><p>(96.3; 100)</p></td><td><p>1134</p><p>(944; 1360)</p></td><td><p>64</p></td><td><p>95.3%</p><p>(86.9; 99.0)</p></td><td><p>513</p><p>(339; 775)</p></td></tr><tr><td><p>Year 1</p></td><td><p>143</p></td><td><p>79.7%</p><p>(72.2; 86.0)</p></td><td><p>112.3</p><p>(77.5; 162.8)</p></td><td><p>58</p></td><td><p>87.9%</p><p>(76.7; 95.0)</p></td><td><p>143.9</p><p>(88.5; 233.8)</p></td></tr><tr><td><p>Year 3</p></td><td><p>121</p></td><td><p>68.6%</p><p>(59.5; 76.7)</p></td><td><p>75.1</p><p>(48.7; 115.9)</p></td><td><p>52</p></td><td><p>61.5%</p><p>(47.0; 74.7)</p></td><td><p>24.1</p><p>(13.3; 43.8)</p></td></tr><tr><td><p>Year 5</p></td><td><p>117</p></td><td><p>58.1%</p><p>(48.6; 67.2)</p></td><td><p>55.8</p><p>(35.7; 87.5)</p></td><td><p>48</p></td><td><p>54.2%</p><p>(39.2; 68.6)</p></td><td><p>16.8</p><p>(9.0; 31.3)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohort.</p><p><strong><sup>(1) </sup></strong>blood sampling performed 21 to 48 days post vaccination</p><p>*rSBA analysis performed at PHE laboratories</p><p>**hSBA analysis performed at GSK laboratories</p><p>&nbsp;</p><p>rSBA and hSBA titres were determined over a period of 10 years in children initially vaccinated with one dose of Nimenrix or MenC-CRM at 12 to 23 months of age in Study MenACWY-TT-027. Persistence of SBA titres was evaluated in two extension studies: MenACWY-TT-032 (up to 5 years) and MenACWY-TT-100 (up to 10 years). Study MenACWY-TT-100 also evaluated the response to a single booster dose of Nimenrix administered 10 years following the initial vaccination with Nimenrix or MenC-CRM. Results are shown in Table 6 (see section 4.4).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:659px"><thead><tr><td colspan="9"><p><strong>Table 6:&nbsp; rSBA and hSBA titres following a single dose of Nimenrix (or MenC-CRM) in toddlers aged 12‑23&nbsp;months, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)</strong></p></td></tr><tr><td rowspan="2"><p><strong>Meningococcal group</strong></p></td><td rowspan="2"><p><strong>Vaccine group</strong></p></td><td rowspan="2"><p><strong>Time point</strong></p><p><strong>&nbsp;</strong></p></td><td colspan="3"><p><strong>rSBA*</strong></p></td><td colspan="3"><p><strong>hSBA**</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td rowspan="5"><p><strong>A</strong></p></td><td rowspan="5"><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1) </sup></p></td><td><p>222</p></td><td><p>100%<br />(98.4; 100)</p></td><td><p>3707<br />(3327; 4129)</p></td><td><p>217</p></td><td><p>91.2%<br />(86.7; 94.6)</p></td><td><p>59.0<br />(49.3; 70.6)</p></td></tr><tr><td><p>Year 4<sup>(2)</sup></p></td><td><p>45</p></td><td style="vertical-align:top"><p>64.4%</p><p>(48.8; 78.1)</p></td><td><p>35.1</p><p>(19.4; 63.4)</p></td><td><p>44</p></td><td style="vertical-align:top"><p>52.3%</p><p>(36.7; 67.5)</p></td><td><p>8.8</p><p>(5.4; 14.2)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>49</p></td><td><p>73.5%</p><p>(58.9; 85.1)</p></td><td><p>37.4</p><p>(22.1; 63.2)</p></td><td><p>45</p></td><td><p>35.6%</p><p>(21.9: 51.2)</p></td><td><p>5.2</p><p>(3.4; 7.8)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>62</p></td><td><p>66.1%</p><p>(53.0; 77.7)</p></td><td><p>28.9</p><p>(16.4; 51.0)</p></td><td><p>59</p></td><td><p>25.4%</p><p>(15.0; 38.4)</p></td><td><p>4.2</p><p>(3.0; 5.9)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>62</p></td><td><p>98.4%<br />(91.3; 100)</p></td><td><p>5122<br />(3726; 7043)</p></td><td><p>62</p></td><td><p>100%<br />(94.2; 100)</p></td><td><p>1534<br />(1112; 2117)</p></td></tr><tr><td rowspan="10"><p><strong>C</strong></p></td><td rowspan="5"><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>220</p></td><td><p>100%<br />(98.3; 100)</p></td><td><p>879<br />(779; 991)</p></td><td><p>221</p></td><td><p>99.1%<br />(96.8; 99.9)</p></td><td><p>190<br />(165; 219)</p></td></tr><tr><td><p>Year 4<sup>(2)</sup></p></td><td><p>45</p></td><td><p>97.8%</p><p>(88.2; 99.9)</p></td><td><p>110</p><p>(62.7; 192)</p></td><td><p>45</p></td><td><p>97.8%</p><p>(88.2; 99.9)</p></td><td><p>370</p><p>(214; 640)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>49</p></td><td><p>77.6%</p><p>(63.4; 88.2)</p></td><td><p>48.9</p><p>(28.5; 84.0)</p></td><td><p>48</p></td><td><p>91.7%</p><p>(80.0; 97.7)</p></td><td><p>216</p><p>(124; 379)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>62</p></td><td><p>82.3%</p><p>(70.5; 90.8)</p></td><td><p>128</p><p>(71.1; 231)</p></td><td><p>60</p></td><td><p>91.7%</p><p>(81.6; 97.2)</p></td><td><p>349</p><p>(197; 619)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>62</p></td><td><p>100%<br />(94.2; 100)</p></td><td><p>7164<br />(5478; 9368)</p></td><td><p>59</p></td><td><p>100%<br />(93.9; 100)</p></td><td><p>33960<br />(23890; 48274)</p></td></tr><tr><td rowspan="5"><p><strong>MenC-CRM</strong></p><p><strong>vaccine</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>68</p></td><td><p>98.5%<br />(92.1; 100)</p></td><td><p>415<br />(297; 580)</p></td><td><p>68</p></td><td><p>72.1%<br />(59.9; 82.3)</p></td><td><p>21.2<br />(13.9; 32.3)</p></td></tr><tr><td><p>Year 4<sup>(2)</sup></p></td><td><p>10</p></td><td><p>80.0%</p><p>(44.4; 97.5)</p></td><td><p>137</p><p>(22.6; 832)</p></td><td><p>10</p></td><td><p>70.0%</p><p>(34.8; 93.3)</p></td><td><p>91.9</p><p>(9.8; 859)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>11</p></td><td><p>63.6%</p><p>(30.8; 89.1)</p></td><td><p>26.5</p><p>(6.5; 107)</p></td><td><p>11</p></td><td><p>90.9%</p><p>(58.7; 99.8)</p></td><td><p>109</p><p>(21.2; 557)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>16</p></td><td><p>87.5%</p><p>(61.7; 98.4)</p></td><td><p>86.7<br />(29.0; 259)</p></td><td><p>15</p></td><td><p>93.3%</p><p>(68.1; 99.8)</p></td><td><p>117</p><p>(40.0; 344)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>16</p></td><td><p>100%<br />(79.4; 100)</p></td><td><p>5793<br />(3631; 9242)</p></td><td><p>15</p></td><td><p>100%<br />(78.2; 100)</p></td><td><p>42559<br />(20106; 90086)</p></td></tr><tr><td rowspan="5"><p><strong>W-135</strong></p></td><td rowspan="5"><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>222</p></td><td><p>100%<br />(98.4; 100)</p></td><td><p>5395<br />(4870; 5976)</p></td><td><p>177</p></td><td><p>79.7%<br />(73.0; 85.3)</p></td><td><p>38.8<br />(29.7; 50.6)</p></td></tr><tr><td><p>Year 4<sup>(2)</sup></p></td><td><p>45</p></td><td><p>60.0%</p><p>(44.3; 74.3)</p></td><td><p>50.8</p><p>(24.0; 108)</p></td><td><p>45</p></td><td><p>84.4%</p><p>(70.5; 93.5)</p></td><td><p>76.9</p><p>(44.0; 134)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>49</p></td><td><p>34.7%</p><p>(21.7; 49.6)</p></td><td><p>18.2</p><p>(9.3; 35.3)</p></td><td><p>46</p></td><td><p>82.6%</p><p>(68.6; 92.2)</p></td><td><p>59.7</p><p>(35.1; 101)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>62</p></td><td><p>30.6%</p><p>(19.6; 43.7)</p></td><td><p>15.8</p><p>(9.1; 27.6)</p></td><td><p>52</p></td><td><p>44.2%</p><p>(30.5; 58.7)</p></td><td><p>7.7</p><p>(4.9; 12.2)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>62</p></td><td><p>100%<br />(94.2; 100)</p></td><td><p>25911<br />(19120; 35115)</p></td><td><p>62</p></td><td><p>100%<br />(94.2; 100)</p></td><td><p>11925<br />(8716; 16316)</p></td></tr><tr><td rowspan="5"><p><strong>Y</strong></p></td><td rowspan="5"><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>222</p></td><td><p>100%<br />(98.4; 100)</p></td><td><p>2824<br />(2529; 3153)</p></td><td><p>201</p></td><td><p>66.7%<br />(59.7; 73.1)</p></td><td><p>24.4<br />(18.6; 32.1)</p></td></tr><tr><td><p>Year 4<sup>(2)</sup></p></td><td><p>45</p></td><td><p>62.2%</p><p>(46.5; 76.2)</p></td><td><p>44.9</p><p>(22.6; 89.3)</p></td><td><p>41</p></td><td><p>87.8%</p><p>(73.8; 95.9)</p></td><td><p>74.6</p><p>(44.5; 125)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>49</p></td><td><p>42.9%</p><p>(28.8; 57.8)</p></td><td><p>20.6</p><p>(10.9; 39.2)</p></td><td><p>45</p></td><td><p>80.0%</p><p>(65.4; 90.4)</p></td><td><p>70.6</p><p>(38.7; 129)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>62</p></td><td><p>45.2%</p><p>(32.5; 58.3)</p></td><td><p>27.4</p><p>(14.7; 51.0)</p></td><td><p>56</p></td><td><p>42.9%</p><p>(29.7; 56.8)</p></td><td><p>9.1</p><p>(5.5; 15.1)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>62</p></td><td><p>98.4%<br />(91.3; 100)</p></td><td><p>7661<br />(5263; 11150)</p></td><td><p>61</p></td><td><p>100%<br />(94.1; 100)</p></td><td><p>12154<br />(9661; 15291)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohorts for 1 month and 5 years post vaccination and the booster ATP cohort. Subjects with a suboptimal response to meningococcal group C (defined as SBA titre below the pre-defined assay cut-off) were to receive an additional dose of MenC vaccine before Year 6. These subjects were excluded from the analysis at Years 4 and 5 but included in the analysis at Year 10.</p><p>(1)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-027</p><p>(2)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-032</p><p>(3)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-100</p><p>(4)&nbsp;&nbsp;&nbsp; Blood sampling was performed 1 month after a booster dose at Year 10.</p><p>*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for subsequent sampling time points.</p><p>** hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in Study MenACWY-TT‑100.</p><p>&nbsp;</p><p><em>Persistence of booster response</em></p><p>Study MenACWY-TT-102 evaluated the persistence of SBA titres up to 6&nbsp;years after a booster dose of Nimenrix or MenC-CRM<sub>197</sub> administered in Study MenACWY-TT-048 to children who initially received the same vaccine at 12&nbsp;to 23 months of age in Study MenACWY-TT-039. A single booster dose was administered 4&nbsp;years after the initial vaccination. Results are shown in Table 7 (see&nbsp;section&nbsp;4.4).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:667px"><thead><tr><td colspan="9"><p><strong>Table 7:&nbsp;&nbsp;&nbsp;&nbsp; rSBA and hSBA titres following a single dose of Nimenrix (or MenC-CRM) in toddlers aged 12‑23&nbsp;months, persistence at 4 years and response following a booster 4 years after initial vaccination, and persistence up to 6 years following booster vaccination (Studies MenACWY-TT-039/048/102)</strong></p></td></tr><tr><td rowspan="2"><p><strong>Meningo-coccal group</strong></p></td><td rowspan="2"><p><strong>Vaccine group</strong></p></td><td rowspan="2"><p><strong>Time point</strong></p></td><td colspan="3"><p><strong>rSBA*</strong></p></td><td colspan="3"><p><strong>hSBA**</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td rowspan="5"><p><strong>A</strong></p></td><td rowspan="5"><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>354</p></td><td><p>99.7%</p><p>(98.4; 100)</p></td><td><p>2205</p><p>(2008; 2422)</p></td><td><p>338</p></td><td><p>77.2%</p><p>(72.4; 81.6)</p></td><td><p>19.0</p><p>(16.4; 22.1)</p></td></tr><tr><td><p>Year 4<sup>(2)</sup></p><p>(Pre-Nimenrix booster)</p></td><td><p>212</p></td><td><p>74.5%</p><p>(68.1; 80.2)</p></td><td><p>112</p><p>(80.3; 156)</p></td><td><p>187</p></td><td style="vertical-align:top"><p>28.9%</p><p>(22.5; 35.9)</p></td><td><p>4.8</p><p>(3.9; 5.9)</p></td></tr><tr><td><p>(Post-booster)<sup>(2,3)</sup></p></td><td><p>214</p></td><td><p>100%</p><p>(98.3; 100)</p></td><td><p>7173</p><p>(6389; 8054)</p></td><td><p>202</p></td><td><p>99.5%</p><p>(97.3; 100)</p></td><td><p>1343</p><p>(1119; 1612)</p></td></tr><tr><td><p>5 years after booster dose<sup>(4)</sup></p></td><td><p>137</p></td><td><p>89.8%</p><p>(83.4; 94.3)</p></td><td><p>229</p><p>(163; 322)</p></td><td><p>135</p></td><td><p>53.3%</p><p>(44.6; 62.0)</p></td><td><p>13.2</p><p>(9.6; 18.3)</p></td></tr><tr><td><p>6 years after booster dose<sup>(4)</sup></p></td><td><p>134</p></td><td><p>92.5%</p><p>(86.7; 96.4)</p></td><td><p>297</p><p>(214; 413)</p></td><td><p>130</p></td><td><p>58.5%</p><p>(49.5; 67.0)</p></td><td><p>14.4</p><p>(10.5; 19.7)</p></td></tr><tr><td><p><strong>C</strong></p></td><td><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>354</p></td><td><p>99.7%</p><p>(98.4; 100)</p></td><td><p>478</p><p>(437; 522)</p></td><td><p>341</p></td><td><p>98.5%</p><p>(96.6; 99.5)</p></td><td><p>196<br />(175; 219)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p>Year 4<sup>(2)</sup></p><p>(Pre-Nimenrix booster)</p></td><td><p>213</p></td><td><p>39.9%</p><p>(33.3; 46.8)</p></td><td><p>12.1</p><p>(9.6; 15.2)</p></td><td><p>200</p></td><td><p>73.0%</p><p>(66.3; 79.0)</p></td><td><p>31.2</p><p>(23.0; 42.2)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p>(Post-booster)<sup>(2,3)</sup></p></td><td><p>215</p></td><td><p>100%</p><p>(98.3; 100)</p></td><td><p>4512</p><p>(3936; 5172)</p></td><td><p>209</p></td><td><p>100%<br />(98.3; 100)</p></td><td><p>15831</p><p>(13626; 18394)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p>5 years after booster dose<sup>(4)</sup></p></td><td><p>137</p></td><td><p>80.3%</p><p>(72.6; 86.6)</p></td><td><p>66.0</p><p>(48.1; 90.5)</p></td><td><p>136</p></td><td><p>99.3%</p><p>(96.0; 100)</p></td><td><p>337</p><p>(261; 435)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p>6 years after booster dose<sup>(4)</sup></p></td><td><p>134</p></td><td><p>71.6%</p><p>(63.2; 79.1)</p></td><td><p>39.6</p><p>(28.6; 54.6)</p></td><td><p>130</p></td><td><p>97.7%</p><p>(93.4; 99.5)</p></td><td><p>259</p><p>(195; 345)</p></td></tr><tr><td><p>&nbsp;</p></td><td rowspan="4"><p><strong>MenC-CRM</strong></p><p><strong>vaccine</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>121</p></td><td><p>97.5%</p><p>(92.9; 99.5)</p></td><td><p>212</p><p>(170; 265)</p></td><td><p>116</p></td><td><p>81.9%</p><p>(73.7; 88.4)</p></td><td><p>40.3</p><p>(29.5; 55.1)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Year 4<sup>(2)</sup></p><p>(Pre-MenC-CRM<sub>197</sub> booster)</p></td><td><p>43</p></td><td><p>37.2%</p><p>(23.0; 53.3)</p></td><td><p>14.3</p><p>(7.7; 26.5)</p></td><td><p>31</p></td><td><p>48.4%</p><p>(30.2; 66.9)</p></td><td><p>11.9</p><p>(5.1; 27.6)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>(Post-booster)<sup>(2,3)</sup></p></td><td><p>43</p></td><td><p>100%</p><p>(91.8; 100)</p></td><td><p>3718</p><p>(2596; 5326)</p></td><td><p>33</p></td><td><p>100%</p><p>(89.4; 100)</p></td><td><p>8646</p><p>(5887; 12699)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>5 years after booster dose<sup>(4)</sup></p></td><td><p>23</p></td><td><p>78.3%</p><p>(56.3; 92.5)</p></td><td><p>47.3</p><p>(19.0; 118)</p></td><td><p>23</p></td><td><p>100%</p><p>(85.2; 100)</p></td><td><p>241</p><p>(139; 420)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>6 years after booster dose<sup>(4)</sup></p></td><td><p>23</p></td><td><p>65.2%</p><p>(42.7; 83.6)</p></td><td><p>33.0</p><p>(14.7; 74.2)</p></td><td><p>23</p></td><td><p>95.7%</p><p>(78.1; 99.9)</p></td><td><p>169</p><p>(94.1; 305)</p></td></tr><tr><td><p><strong>W-135</strong></p></td><td><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>354</p></td><td><p>100%</p><p>(99.0; 100)</p></td><td><p>2682</p><p>(2453; 2932)</p></td><td><p>336</p></td><td><p>87.5%</p><p>(83.5; 90.8)</p></td><td><p>48.9</p><p>(41.2; 58.0)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p>Year 4<sup>(2)</sup></p><p>(Pre-Nimenrix booster)</p></td><td><p>213</p></td><td><p>48.8%</p><p>(41.9; 55.7)</p></td><td><p>30.2</p><p>(21.9; 41.5)</p></td><td><p>158</p></td><td><p>81.6%</p><p>(74.7; 87.3)</p></td><td><p>48.3</p><p>(36.5; 63.9)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p>(Post-booster)<sup>(2,3)</sup></p></td><td><p>215</p></td><td><p>100%</p><p>(98.3; 100)</p></td><td><p>10950</p><p>(9531; 12579)</p></td><td><p>192</p></td><td><p>100%</p><p>(98.1; 100)</p></td><td><p>14411</p><p>(12972&nbsp;&nbsp; ; 16010)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p>5 years after booster dose<sup>(4)</sup></p></td><td><p>137</p></td><td><p>88.3%</p><p>(81.7; 93.2)</p></td><td><p>184</p><p>(130; 261)</p></td><td><p>136</p></td><td><p>100%</p><p>(97.3; 100)</p></td><td><p>327</p><p>(276; 388)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p>6 years after booster dose<sup>(4)</sup></p></td><td><p>134</p></td><td><p>85.8%</p><p>(78.7; 91.2)</p></td><td><p>172</p><p>(118; 251)</p></td><td><p>133</p></td><td><p>98.5%</p><p>(94.7; 99.8)</p></td><td><p>314</p><p>(255; 388)</p></td></tr><tr><td rowspan="5"><p><strong>Y</strong></p></td><td rowspan="5"><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>354</p></td><td><p>100%</p><p>(99.0; 100)</p></td><td><p>2729</p><p>(2473; 3013)</p></td><td><p>329</p></td><td><p>79.3%</p><p>(74.5; 83.6)</p></td><td><p>30.9</p><p>(25.8; 37.1)</p></td></tr><tr><td><p>Year 4<sup>(2)</sup></p><p>(Pre-Nimenrix booster)</p></td><td><p>213</p></td><td><p>58.2%</p><p>(51.3; 64.9)</p></td><td><p>37.3</p><p>(27.6; 50.4)</p></td><td><p>123</p></td><td><p>65.9%</p><p>(56.8; 74.2)</p></td><td><p>30.2</p><p>(20.2; 45.0)</p></td></tr><tr><td><p>(Post-booster)<sup>(2,3)</sup></p></td><td><p>215</p></td><td><p>100%</p><p>(98.3; 100)</p></td><td><p>4585</p><p>(4129; 5093)</p></td><td><p>173</p></td><td><p>100%</p><p>(97.9; 100)</p></td><td><p>6776</p><p>(5961; 7701)</p></td></tr><tr><td><p>5 years after booster dose<sup>(4)</sup></p></td><td><p>137</p></td><td><p>92.7%</p><p>(87.0; 96.4)</p></td><td><p>265</p><p>(191; 368)</p></td><td><p>137</p></td><td><p>97.8%</p><p>(93.7; 99.5)</p></td><td><p>399</p><p>(321; 495)</p></td></tr><tr><td><p>6 years after booster dose<sup>(4)</sup></p></td><td><p>134</p></td><td><p>94.0%</p><p>(88.6; 97.4)</p></td><td><p>260</p><p>(189; 359)</p></td><td><p>131</p></td><td><p>97.7%</p><p>(93.5; 99.5)</p></td><td><p>316</p><p>(253; 394)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohort for each time point.</p><p>(1)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-039</p><p>(2)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-048</p><p>(3)&nbsp;&nbsp;&nbsp; Blood sampling was performed 1 month after a booster dose at Year 4.</p><p>(4)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-102</p><p>* rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for the subsequent sampling time points.</p><p>**hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in Study MenACWY‑TT-102.</p><p>&nbsp;</p><p><u>Immunogenicity in children aged 2-10 years</u></p><p>&nbsp;</p><p>In Study MenACWY-TT-081, a single dose of Nimenrix was demonstrated to be non-inferior to another licensed MenC-CRM vaccine in terms of vaccine response to group C [94.8% (95% CI: 91.4; 97.1) and 95.7% (95% CI: 89.2; 98.8), respectively]. The GMT was lower for the Nimenrix group [2795 (95% CI: 2393; 3263)] versus the MenC-CRM vaccine [5292 (95% CI: 3815; 7340)].</p><p>&nbsp;</p><p>In Study MenACWY-TT-038, a single dose of Nimenrix was demonstrated to be non-inferior to the licensed ACWY‑PS vaccine in terms of vaccine response to the four meningococcal groups as shown in Table&nbsp;8.</p><p>&nbsp;</p><p><strong>Table 8: rSBA* titres following a single dose of Nimenrix (or ACWY-PS) in children aged 2‑10&nbsp;years (Study MenACWY-TT-038)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Meningo-coccal group</strong></p></td><td colspan="3"><p><strong>Nimenrix</strong><strong><sup>(1)</sup></strong></p></td><td colspan="3"><p><strong>ACWY-PS vaccine</strong><strong><sup>(1)</sup></strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>VR</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>VR</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td><p>A</p></td><td><p>594</p></td><td><p>89.1%</p><p>(86.3; 91.5)</p></td><td><p>6343</p><p>(5998; 6708)</p></td><td><p>192</p></td><td><p>64.6%</p><p>(57.4; 71.3)</p></td><td><p>2283</p><p>(2023; 2577)</p></td></tr><tr><td><p>C</p></td><td><p>691</p></td><td><p>96.1%</p><p>(94.4; 97.4)</p></td><td><p>4813</p><p>(4342; 5335)</p></td><td><p>234</p></td><td><p>89.7%</p><p>(85.1; 93.3)</p></td><td><p>1317</p><p>(1043; 1663)</p></td></tr><tr><td><p>W-135</p></td><td><p>691</p></td><td><p>97.4%</p><p>(95.9; 98.4)</p></td><td><p>11543</p><p>(10873; 12255)</p></td><td><p>236</p></td><td><p>82.6%</p><p>(77.2; 87.2)</p></td><td><p>2158</p><p>(1815; 2565)</p></td></tr><tr><td><p>Y</p></td><td><p>723</p></td><td><p>92.7%</p><p>(90.5; 94.5)</p></td><td><p>10825</p><p>(10233; 11452)</p></td><td><p>240</p></td><td><p>68.8%</p><p>(62.5; 74.6)</p></td><td><p>2613</p><p>(2237; 3052)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohort.</p><p><sup>(1) </sup>Blood sampling performed 1 month post vaccination</p><p>VR: vaccine response defined as the proportion of subjects with:</p><ul><li>rSBA titres &ge;32 for initially seronegative subjects (i.e., pre-vaccination rSBA titre &lt;8)</li></ul><ul><li>at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects (i.e., pre-vaccination rSBA titre &ge;8)</li></ul><p>* rSBA analysis performed at GSK laboratories</p><p>&nbsp;</p><p>Persistence of SBA titres was evaluated in children initially vaccinated in Study MenACWY-TT-081 as shown in Table 9 (see section 4.4).</p><p>&nbsp;</p><p><strong>Table 9:&nbsp; rSBA and hSBA titres up to 44 months following Nimenrix (or MenC-CRM) in children aged 2‑10 years at time of vaccination (Study MenACWY-TT-088)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:640px"><tbody><tr><td rowspan="2"><p><strong>Meningococcal</strong></p><p><strong>group</strong></p></td><td rowspan="2"><p><strong>Vaccine group</strong></p></td><td rowspan="2"><p><strong>Time point</strong></p><p><strong>(months)</strong></p></td><td colspan="3"><p><strong>rSBA*</strong></p></td><td colspan="3"><p><strong>hSBA**</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td rowspan="2"><p><strong>A</strong></p></td><td rowspan="2"><p><strong>Nimenrix</strong></p></td><td><p>32</p></td><td><p>193</p></td><td><p>86.5%</p><p>(80.9; 91.0)</p></td><td><p>196</p><p>(144; 267)</p></td><td><p>90</p></td><td><p>25.6%</p><p>(16.9; 35.8)</p></td><td><p>4.6</p><p>(3.3; 6.3)</p></td></tr><tr><td><p>44</p></td><td><p>189</p></td><td><p>85.7%</p><p>(79.9; 90.4)</p></td><td><p>307</p><p>(224; 423)</p></td><td><p>89</p></td><td><p>25.8%</p><p>(17.1; 36.2)</p></td><td><p>4.8</p><p>(3.4; 6.7)</p></td></tr><tr><td rowspan="4"><p><strong>C</strong></p></td><td rowspan="2"><p><strong>Nimenrix</strong></p></td><td><p>32</p></td><td><p>192</p></td><td><p>64.6%</p><p>(57.4; 71.3)</p></td><td><p>34.8</p><p>(26.0; 46.4)</p></td><td><p>90</p></td><td><p>95.6%</p><p>(89.0; 98.8)</p></td><td><p>75.9</p><p>(53.4; 108)</p></td></tr><tr><td><p>44</p></td><td><p>189</p></td><td><p>37.0%</p><p>(30.1; 44.3)</p></td><td><p>14.5</p><p>(10.9; 19.2)</p></td><td><p>82</p></td><td><p>76.8%</p><p>(66.2; 85.4)</p></td><td><p>36.4</p><p>(23.1; 57.2)</p></td></tr><tr><td rowspan="2"><p><strong>MenC-CRM vaccine</strong></p></td><td><p>32</p></td><td><p>69</p></td><td><p>76.8%</p><p>(65.1; 86.1)</p></td><td><p>86.5</p><p>(47.3; 158)</p></td><td><p>33</p></td><td><p>90.9%</p><p>(75.7; 98.1)</p></td><td><p>82.2</p><p>(34.6; 196)</p></td></tr><tr><td><p>44</p></td><td><p>66</p></td><td><p>45.5%</p><p>(33.1; 58.2)</p></td><td><p>31.0</p><p>(16.6; 58.0)</p></td><td><p>31</p></td><td><p>64.5%</p><p>(45.4; 80.8)</p></td><td><p>38.8</p><p>(13.3; 113)</p></td></tr><tr><td rowspan="2"><p><strong>W-135</strong></p></td><td rowspan="2"><p><strong>Nimenrix</strong></p></td><td><p>32</p></td><td><p>193</p></td><td><p>77.2%</p><p>(70.6; 82.9)</p></td><td><p>214</p><p>(149; 307)</p></td><td><p>86</p></td><td><p>84.9%</p><p>(75.5; 91.7)</p></td><td><p>69.9</p><p>(48.2; 101)</p></td></tr><tr><td><p>44</p></td><td><p>189</p></td><td><p>68.3%</p><p>(61.1; 74.8)</p></td><td><p>103</p><p>(72.5; 148)</p></td><td><p>87</p></td><td><p>80.5%</p><p>(70.6; 88.2)</p></td><td><p>64.3</p><p>(42.7; 96.8)</p></td></tr><tr><td rowspan="2"><p><strong>Y</strong></p></td><td rowspan="2"><p><strong>Nimenrix</strong></p></td><td><p>32</p></td><td><p>193</p></td><td><p>81.3%</p><p>(75.1; 86.6)</p></td><td><p>227</p><p>(165; 314)</p></td><td><p>91</p></td><td><p>81.3%</p><p>(71.8; 88.7)</p></td><td><p>79.2</p><p>(52.5; 119)</p></td></tr><tr><td><p>44</p></td><td><p>189</p></td><td><p>62.4%</p><p>(55.1; 69.4)</p></td><td><p>78.9</p><p>(54.6; 114)</p></td><td><p>76</p></td><td><p>82.9%</p><p>(72.5; 90.6)</p></td><td><p>127</p><p>(78.0; 206)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohort for persistence adapted for each time point.</p><p>*rSBA analysis performed at PHE laboratories in UK</p><p>** hSBA analysis performed at GSK laboratories</p><p>&nbsp;</p><p>Persistence of hSBA titres was evaluated 1 year after vaccination in children aged 6-10 years who were initially vaccinated in Study MenACWY-TT-027 (Table 10) (see section 4.4).</p><p>&nbsp;</p><p><strong>Table 10: hSBA* titres following a single dose of Nimenrix (or ACWY-PS) in children aged 6‑10&nbsp;years and persistence 1 year following vaccination (Studies MenACWY-TT-027/028)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td rowspan="2"><p><strong>Meningococcal group</strong></p></td><td rowspan="2"><p><strong>Vaccine group</strong></p></td><td colspan="3"><p><strong>1 month post-vaccination</strong></p><p><strong>(Study MenACWY-TT-027)</strong></p></td><td colspan="3"><p><strong>1 year persistence</strong></p><p><strong>(Study MenACWY-TT-028)</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td rowspan="2"><p><strong>A</strong></p></td><td><p><strong>Nimenrix</strong></p></td><td><p>105</p></td><td><p>80.0 %</p><p>(71.1; 87.2)</p></td><td><p>53.4</p><p>(37.3; 76.2)</p></td><td><p>104</p></td><td><p>16.3%</p><p>(9.8; 24.9)</p></td><td><p>3.5</p><p>(2.7; 4.4)</p></td></tr><tr><td><p><strong>ACWY-PS<br />vaccine</strong></p></td><td><p>35</p></td><td><p>25.7%</p><p>(12.5; 43.3)</p></td><td><p>4.1</p><p>(2.6; 6.5)</p></td><td><p>35</p></td><td><p>5.7%</p><p>(0.7; 19.2)</p></td><td><p>2.5</p><p>(1.9; 3.3)</p></td></tr><tr><td rowspan="2"><p><strong>C</strong></p></td><td><p><strong>Nimenrix</strong></p></td><td><p>101</p></td><td><p>89.1%</p><p>(81.3; 94.4)</p></td><td><p>156</p><p>(99.3; 244)</p></td><td><p>105</p></td><td><p>95.2%</p><p>(89.2; 98.4)</p></td><td><p>129</p><p>(95.4; 176)</p></td></tr><tr><td><p><strong>ACWY-PS<br />vaccine</strong></p></td><td><p>38</p></td><td><p>39.5%</p><p>(24.0; 56.6)</p></td><td><p>13.1</p><p>(5.4; 32.0)</p></td><td><p>31</p></td><td><p>32.3%</p><p>(16.7; 51.4)</p></td><td><p>7.7</p><p>(3.5; 17.3)</p></td></tr><tr><td rowspan="2"><p><strong>W-135</strong></p></td><td><p><strong>Nimenrix</strong></p></td><td><p>103</p></td><td><p>95.1%</p><p>(89.0; 98.4)</p></td><td><p>133</p><p>(99.9; 178)</p></td><td><p>103</p></td><td><p>100%</p><p>(96.5; 100)</p></td><td><p>257</p><p>(218; 302)</p></td></tr><tr><td><p><strong>ACWY-PS<br />vaccine</strong></p></td><td><p>35</p></td><td><p>34.3%</p><p>(19.1; 52.2)</p></td><td><p>5.8</p><p>(3.3; 9.9)</p></td><td><p>31</p></td><td><p>12.9%</p><p>(3.6; 29.8)</p></td><td><p>3.4</p><p>(2.0; 5.8)</p></td></tr><tr><td rowspan="2"><p><strong>Y</strong></p></td><td><p><strong>Nimenrix</strong></p></td><td><p>89</p></td><td><p>83.1%</p><p>(73.7;90.2)</p></td><td><p>95.1</p><p>(62.4; 145)</p></td><td><p>106</p></td><td><p>99.1%</p><p>(94.9; 100)</p></td><td><p>265</p><p>(213; 330)</p></td></tr><tr><td><p><strong>ACWY-PS<br />vaccine</strong></p></td><td><p>32</p></td><td><p>43.8%</p><p>(26.4; 62.3)</p></td><td><p>12.5</p><p>(5.6; 27.7)</p></td><td><p>36</p></td><td><p>33.3%</p><p>(18.6; 51.0)</p></td><td><p>9.3</p><p>(4.3; 19.9)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohort for persistence at Year 1.</p><p>hSBA analysis was not performed for children aged 2 to &lt;6 years (at time of vaccination).</p><p>* hSBA analysis performed at GSK laboratories</p><p><u>&nbsp;</u></p><p>SBA titres were determined over a period of 10 years in children initially vaccinated with one dose of Nimenrix or ACWY-PS at 2 to 10 years of age in Study MenACWY-TT-027. Persistence of SBA titres was evaluated in two extension studies: MenACWY-TT-032 (up to 5 years) and MenACWY-TT-100 (up to 10 years). Study MenACWY-TT-100 also evaluated the response to a single booster dose of Nimenrix administered 10&nbsp;years following the initial vaccination with Nimenrix or ACWY-PS. Results are shown in Table&nbsp;11 (see section 4.4).</p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:674px"><thead><tr><td colspan="9"><p><strong>Table 11:</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rSBA and hSBA titres following a single dose of Nimenrix (or ACWY-PS) in children aged 2-10 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)</strong></p></td></tr><tr><td rowspan="2"><p><strong>Meningo-coccal</strong></p><p><strong>group</strong></p></td><td rowspan="2"><p><strong>Vaccine group</strong></p></td><td rowspan="2"><p><strong>Time point</strong></p></td><td colspan="3"><p><strong>rSBA*</strong></p></td><td colspan="3"><p><strong>hSBA**</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td rowspan="10"><p><strong>A</strong></p></td><td rowspan="5"><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>225</p></td><td><p>100%<br />(98.4; 100)</p></td><td><p>7301<br />(6586; 8093)</p></td><td><p>111<sup>(5)</sup></p></td><td><p>81.1%<br />(72.5; 87.9)</p></td><td><p>57.0<br />(40.3; 80.6)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>98</p></td><td><p>90.8%<br />(83.3; 95.7)</p></td><td><p>141<br />(98.2; 203)</p></td><td><p>n/a<sup>(6)</sup></p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td><p>Year 6<sup>(3)</sup></p></td><td><p>98</p></td><td><p>79.6%<br />(70.3; 87.1)</p></td><td><p>107<br />(66.0; 174)</p></td><td><p>90</p></td><td><p>41.1%<br />(30.8; 52.0)</p></td><td><p>6.5<br />(4.8; 8.8)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />(Pre-booster)</p></td><td><p>73</p></td><td><p>89.0%<br />(79.5; 95.1)</p></td><td><p>96.3<br />(57.1; 163)</p></td><td><p>62</p></td><td><p>33.9%</p><p>(22.3; 47.0)</p></td><td><p>4.5</p><p>(3.3; 6.2)</p></td></tr><tr><td><p>(Post-booster)<sup>(3,4)</sup></p></td><td><p>74</p></td><td><p>95.9%<br />(88.6; 99.2)</p></td><td><p>4626<br />(3041; 7039)</p></td><td><p>73</p></td><td><p>100%<br />(95.1; 100)</p></td><td><p>1213<br />(994; 1481)</p></td></tr><tr><td rowspan="5"><p><strong>ACWY-PS<br />vaccine</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>75</p></td><td><p>100%<br />(95.2; 100)</p></td><td><p>2033<br />(1667; 2480)</p></td><td><p>35<sup>(5)</sup></p></td><td><p>25.7%<br />(12.5; 43.3)</p></td><td><p>4.1<br />(2.6; 6.5)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>13</p></td><td><p>15.4%<br />(1.9; 45.4)</p></td><td><p>4.7<br />(3.7; 6.0)</p></td><td><p>n/a<sup>(6)</sup></p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td><p>Year 6<sup>(3)</sup></p></td><td><p>24</p></td><td><p>12.5%<br />(2.7; 32.4)</p></td><td><p>5.8<br />(3.5; 9.6)</p></td><td><p>21</p></td><td><p>33.3%<br />(14.6; 57.0)</p></td><td><p>5.9<br />(3.0; 11.7)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />(Pre-booster)</p></td><td><p>17</p></td><td><p>23.5%<br />(6.8; 49.9)</p></td><td><p>8.0<br />(3.3; 19.3)</p></td><td><p>17</p></td><td><p>29.4%</p><p>(10.3; 56.0)</p></td><td><p>6.2</p><p>(2.4; 15.7)</p></td></tr><tr><td><p>(Post-booster)<sup>(3,4)</sup></p></td><td><p>17</p></td><td><p>100%<br />(80.5; 100)</p></td><td><p>6414<br />(3879; 10608)</p></td><td><p>17</p></td><td><p>100%<br />(80.5; 100)</p></td><td><p>211<br />(131; 340)</p></td></tr><tr><td rowspan="10"><p><strong>C</strong></p></td><td rowspan="5"><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>225</p></td><td><p>100%<br />(98.4; 100)</p></td><td><p>2435<br />(2106; 2816)</p></td><td><p>107<sup>(5)</sup></p></td><td><p>89.7%<br />(82.3; 94.8)</p></td><td><p>155<br />(101; 237)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>98</p></td><td><p>90.8%<br />(83.3; 95.7)</p></td><td><p>79.7<br />(56.0; 113)</p></td><td><p>n/a<sup>(6)</sup></p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td><p>Year 6<sup>(3)</sup></p></td><td><p>98</p></td><td><p>82.7%<br />(73.7; 89.6)</p></td><td><p>193<br />(121; 308)</p></td><td><p>97</p></td><td><p>93.8%<br />(87.0; 97.7)</p></td><td><p>427<br />(261; 700)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />(Pre-booster)</p></td><td><p>74</p></td><td><p>85.1%<br />(75.0; 92.3)</p></td><td><p>181<br />(106; 310)</p></td><td><p>73</p></td><td><p>91.8%</p><p>(83.0; 96.9)</p></td><td><p>222</p><p>(129; 380)</p></td></tr><tr><td><p>(Post-booster)<sup>(3,4)</sup></p></td><td><p>74</p></td><td><p>100%<br />(95.1; 100)</p></td><td><p>4020<br />(3319; 4869)</p></td><td><p>71</p></td><td><p>100%<br />(94.9; 100)</p></td><td><p>15544<br />(11735; 20588)</p></td></tr><tr><td rowspan="5"><p><strong>ACWY-PS<br />vaccine</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>74</p></td><td><p>100%<br />(95.1; 100)</p></td><td><p>750<br />(555; 1014)</p></td><td><p>38<sup>(5)</sup></p></td><td><p>39.5%<br />(24.0; 56.6)</p></td><td><p>13.1<br />(5.4; 32.0)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>13</p></td><td><p>100%<br />(75.3; 100)</p></td><td><p>128<br />(56.4; 291)</p></td><td><p>n/a<sup>(6)</sup></p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td><p>Year 6<sup>(3)</sup></p></td><td><p>24</p></td><td><p>79.2%<br />(57.8; 92.9)</p></td><td><p>98.7<br />(42.2; 231)</p></td><td><p>24</p></td><td><p>100%<br />(85.8; 100)</p></td><td><p>235<br />(122; 451)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />(Pre-booster)</p></td><td><p>17</p></td><td><p>76.5%<br />(50.1; 93.2)</p></td><td><p>96.2<br />(28.9; 320)</p></td><td><p>17</p></td><td><p>100%</p><p>(80.5; 100)</p></td><td><p>99.1</p><p>(35.8; 274)</p></td></tr><tr><td><p>(Post-booster)<sup>(3,4)</sup></p></td><td><p>17</p></td><td><p>100%<br />(80.5; 100)</p></td><td><p>15101</p><p>(7099; 32122)</p></td><td><p>17</p></td><td><p>94.1<br />(71.3; 99.9)</p></td><td><p>44794<br />(10112; 198440)</p></td></tr><tr><td rowspan="10"><p><strong>W-135</strong></p></td><td rowspan="5"><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>225</p></td><td><p>100%<br />(98.4; 100)</p></td><td><p>11777<br />(10666; 13004)</p></td><td><p>107<sup>(5)</sup></p></td><td><p>95.3%<br />(89.4; 98.5)</p></td><td><p>134<br />(101; 178)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>98</p></td><td><p>78.6%<br />(69.1; 86.2)</p></td><td><p>209<br />(128; 340)</p></td><td><p>n/a<sup>(6)</sup></p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td><p>Year 6<sup>(3)</sup></p></td><td><p>98</p></td><td><p>73.5%<br />(63.6; 81.9)</p></td><td><p>265<br />(155; 454)</p></td><td><p>92</p></td><td><p>81.5%<br />(72.1; 88.9)</p></td><td><p>62.5<br />(42.0; 93.1)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />(Pre-booster)</p></td><td><p>74</p></td><td><p>68.9%<br />(57.1; 79.2)</p></td><td><p>206<br />(109; 392)</p></td><td><p>59</p></td><td><p>61.0%</p><p>(47.4; 73.5)</p></td><td><p>17.5</p><p>(10.5; 29.2)</p></td></tr><tr><td><p>(Post-booster)<sup>(3,4)</sup></p></td><td><p>74</p></td><td><p>100%<br />(95.1; 100)</p></td><td><p>27944<br />(22214; 35153)</p></td><td><p>74</p></td><td><p>100%<br />(95.1; 100)</p></td><td><p>6965<br />(5274; 9198)</p></td></tr><tr><td rowspan="5"><p><strong>ACWY-PS<br />vaccine</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>75</p></td><td><p>100%<br />(95.2; 100)</p></td><td><p>2186<br />(1723; 2774)</p></td><td><p>35<sup>(5)</sup></p></td><td><p>34.3%<br />(19.1; 52.2)</p></td><td><p>5.8<br />(3.3, 9.9)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>13</p></td><td><p>0%<br />(0.0; 24.7)</p></td><td><p>4.0<br />(4.0; 4.0)</p></td><td><p>n/a<sup>(6)</sup></p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td><p>Year 6<sup>(3)</sup></p></td><td><p>24</p></td><td><p>12.5%<br />(2.7; 32.4)</p></td><td><p>7.6<br />(3.7; 15.6)</p></td><td><p>23</p></td><td><p>30.4%<br />(13.2; 52.9)</p></td><td><p>7.0<br />(2.9; 16.9)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />(Pre-booster)</p></td><td><p>17</p></td><td><p>23.5%<br />(6.8; 49.9)</p></td><td><p>15.4<br />(4.2; 56.4)</p></td><td><p>15</p></td><td><p>26.7%</p><p>(7.8; 55.1)</p></td><td><p>4.1</p><p>(2.0; 8.5)</p></td></tr><tr><td><p>(Post-booster)<sup>(3,4)</sup></p></td><td><p>17</p></td><td><p>94.1%<br />(71.3; 99.9)</p></td><td><p>10463<br />(3254; 33646)</p></td><td><p>15</p></td><td><p>100%<br />(78.2; 100)</p></td><td><p>200<br />(101; 395)</p></td></tr><tr><td rowspan="10"><p><strong>Y</strong></p></td><td rowspan="5"><p><strong>Nimenrix</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>225</p></td><td><p>100%<br />(98.4; 100)</p></td><td><p>6641<br />(6044; 7297)</p></td><td><p>94<sup>(5)</sup></p></td><td><p>83.0%<br />(73.8; 89.9)</p></td><td><p>93.7<br />(62.1; 141)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>98</p></td><td><p>78.6%<br />(69.1; 86.2)</p></td><td><p>143<br />(88.0; 233)</p></td><td><p>n/a<sup>(6)</sup></p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td><p>Year 6<sup>(3)</sup></p></td><td><p>98</p></td><td><p>71.4%<br />(61.4; 80.1)</p></td><td><p>136<br />(82.6; 225)</p></td><td><p>89</p></td><td><p>65.2%<br />(54.3; 75.0)</p></td><td><p>40.3<br />(23.9; 68.1)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>74</p></td><td><p>67.6%</p><p>(55.7; 78.0)</p></td><td><p>98.5</p><p>(54.3; 179)</p></td><td><p>65</p></td><td><p>72.3%</p><p>(59.8; 82.7)</p></td><td><p>35.7</p><p>(21.0; 60.6)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>74</p></td><td><p>100%<br />(95.1; 100)</p></td><td><p>7530<br />(5828; 9729)</p></td><td><p>74</p></td><td><p>100%<br />(95.1; 100)</p></td><td><p>11127<br />(8909; 13898)</p></td></tr><tr><td rowspan="5"><p><strong>ACWY-PS<br />vaccine</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>75</p></td><td><p>100%<br />(95.2; 100)</p></td><td><p>1410<br />(1086; 1831)</p></td><td><p>32<sup>(5)</sup></p></td><td><p>43.8%<br />(26.4; 62.3)</p></td><td><p>12.5<br />(5.6; 27.7)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>13</p></td><td><p>7.7%<br />(0.2; 36.0)</p></td><td><p>5.5<br />(2.7; 11.1)</p></td><td><p>n/a<sup>(6)</sup></p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td><p>Year 6<sup>(3)</sup></p></td><td><p>24</p></td><td><p>20.8%<br />(7.1; 42.2)</p></td><td><p>11.6<br />(4.7; 28.7)</p></td><td><p>24</p></td><td><p>25.0%<br />(9.8; 46.7)</p></td><td><p>7.3<br />(2.7; 19.8)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>17</p></td><td><p>17.6%</p><p>(3.8; 43.4)</p></td><td><p>10.2</p><p>(3.5; 30.2)</p></td><td><p>14</p></td><td><p>35.7%</p><p>(12.8; 64.9)</p></td><td><p>7.8</p><p>(2.5; 24.4)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>17</p></td><td><p>100%<br />(80.5; 100)</p></td><td><p>6959<br />(3637; 13317)</p></td><td><p>17</p></td><td><p>100%<br />(80.5; 100)</p></td><td><p>454<br />(215; 960)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohort for each time point. Subjects with a suboptimal response to meningococcal group C (defined as SBA titre below the pre-defined assay cut-off) were to receive an additional dose of MenC vaccine before Year 6. These subjects were excluded from the analysis at Year 5 but included in the analyses at Years 6 and 10.</p><p>(1)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-027</p><p>(2)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-032</p><p>(3)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-100</p><p>(4)&nbsp;&nbsp;&nbsp; Blood sampling was performed 1 month after a booster dose at Year 10.</p><p>(5)&nbsp;&nbsp;&nbsp; Includes children aged 6 to &lt;11 years. hSBA analysis was not performed for children aged 2 to &lt;6 years (at time of vaccination).</p><p>(6)&nbsp;&nbsp;&nbsp; Per the protocol for Study MenACWY-TT-032, hSBA was not measured for this age group at Year 5.</p><p>*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for subsequent sampling time points.</p><p>**hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in Study MenACWY‑TT-100.</p><p><u>&nbsp;</u></p><p><u>Immunogenicity in adolescents aged 11-17 years and adults aged &ge;18 years</u></p><p>&nbsp;</p><p>In two clinical studies, conducted in adolescents aged 11-17 years (Study MenACWY-TT-036) and in adults aged 18-55 years (Study MenACWY-TT-035), either one dose of Nimenrix or one dose of the ACWY-PS vaccine was administered.</p><p>&nbsp;</p><p>Nimenrix was demonstrated to be immunologically non-inferior to the ACWY-PS vaccine in terms of vaccine response as shown in Table 12.</p><p>&nbsp;</p><p><strong>Table 12:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rSBA* titres following a single dose of Nimenrix (or ACWY-PS) in adolescents aged 11-17 years and adults aged 18-55 years (Studies MenACWY-TT-035/036)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td rowspan="2"><p><strong>Meningo-coccal</strong></p><p><strong>group</strong></p></td><td rowspan="2"><p><strong>Vaccine group</strong></p></td><td colspan="3"><p><strong>Study MenACWY-TT-036</strong></p><p><strong>(11-17 years)<sup>(1)</sup></strong></p></td><td colspan="3"><p><strong>Study MenACWY-TT-035</strong></p><p><strong>(18-55 years)<sup>(1)</sup></strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>VR</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>VR</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td rowspan="4"><p><strong>A</strong></p></td><td style="vertical-align:top"><p><strong>Nimenrix</strong></p></td><td><p>553</p></td><td><p>85.4%</p><p>(82.1; 88.2)</p></td><td><p>5928</p><p>(5557; 6324)</p></td><td><p>743</p></td><td><p>80.1%</p><p>(77.0; 82.9)</p></td><td><p>3625</p><p>(3372; 3897)</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACWY-PS vaccine</strong></p></td><td><p>191</p></td><td><p>77.5%</p><p>(70.9; 83.2)</p></td><td><p>2947</p><p>(2612; 3326)</p></td><td><p>252</p></td><td><p>69.8%</p><p>(63.8; 75.4)</p></td><td><p>2127</p><p>(1909; 2370)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nimenrix</strong></p></td><td><p>642</p></td><td><p>97.4%</p><p>(95.8; 98.5)</p></td><td><p>13110</p><p>(11939; 14395)</p></td><td><p>849</p></td><td><p>91.5%</p><p>(89.4; 93.3)</p></td><td><p>8866</p><p>(8011; 9812)</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACWY-PS vaccine</strong></p></td><td><p>211</p></td><td><p>96.7%</p><p>(93.3; 98.7)</p></td><td><p>8222</p><p>(6807; 9930)</p></td><td><p>288</p></td><td><p>92.0%</p><p>(88.3; 94.9)</p></td><td><p>7371</p><p>(6297; 8628)</p></td></tr><tr><td rowspan="2"><p><strong>W-135</strong></p></td><td style="vertical-align:top"><p><strong>Nimenrix</strong></p></td><td><p>639</p></td><td><p>96.4%</p><p>(94.6; 97.7)</p></td><td><p>8247</p><p>(7639; 8903)</p></td><td><p>860</p></td><td><p>90.2%</p><p>(88.1; 92.1)</p></td><td><p>5136</p><p>(4699; 5614)</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACWY-PS vaccine</strong></p></td><td><p>216</p></td><td><p>87.5%</p><p>(82.3; 91.6)</p></td><td><p>2633</p><p>(2299; 3014)</p></td><td><p>283</p></td><td><p>85.5%</p><p>(80.9; 89.4)</p></td><td><p>2461</p><p>(2081; 2911)</p></td></tr><tr><td><p><strong>Y</strong></p></td><td style="vertical-align:top"><p><strong>Nimenrix</strong></p></td><td><p>657</p></td><td><p>93.8%</p><p>(91.6; 95.5)</p></td><td><p>14086</p><p>(13168; 15069)</p></td><td><p>862</p></td><td><p>87.0%</p><p>(84.6; 89.2)</p></td><td><p>7711</p><p>(7100; 8374)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>ACWY-PS vaccine</strong></p></td><td><p>219</p></td><td><p>78.5%</p><p>(72.5; 83.8)</p></td><td><p>5066</p><p>(4463; 5751)</p></td><td><p>288</p></td><td><p>78.8%</p><p>(73.6; 83.4)</p></td><td><p>4314</p><p>(3782; 4921)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohorts.</p><p>(1)&nbsp;&nbsp;&nbsp; Blood sampling performed 1 month post vaccination</p><p>VR: vaccine response defined as the proportion of subjects with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rSBA titres &ge;32 for initially seronegative subjects (i.e., pre-vaccination rSBA titre &lt;8)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects (i.e., pre-vaccination rSBA titre &ge;8)</p><p>*rSBA analysis performed at GSK laboratories</p><p>&nbsp;</p><p>rSBA titres were determined over a period of 10 years in subjects initially vaccinated with one dose of Nimenrix or ACWY-PS at 11 to 17 years of age in Study MenACWY-TT-036. Persistence of rSBA titres was evaluated in two extension studies: MenACWY-TT-043 (up to 5 years) and MenACWY-TT-101 (at 10 years). Study MenACWY-TT-101 also evaluated the response to a single booster dose of Nimenrix administered 10 years following the initial vaccination with Nimenrix or ACWY-PS. Results are shown in Table 13.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:652px"><thead><tr><td colspan="8"><p><strong>Table 13:&nbsp;&nbsp; rSBA* titres following a single dose of Nimenrix (or ACWY-PS) in adolescents aged 11‑17&nbsp;years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-036/043/101)</strong></p></td></tr><tr><td rowspan="22"><p><strong>Meningo-coccal group</strong></p></td><td rowspan="2"><p><strong>Time point</strong></p><p><strong>&nbsp;</strong></p></td><td colspan="3"><p><strong>Nimenrix</strong></p></td><td colspan="3"><p><strong>ACWY-PS vaccine</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td><p>Month 1<sup>(1)</sup></p></td><td><p>674</p></td><td><p>100%<br />(99.5; 100)</p></td><td><p>5929<br />(5557; 6324)</p></td><td><p>224</p></td><td><p>99.6%<br />(97.5; 100)</p></td><td><p>2947</p><p>(2612; 3326)</p></td></tr><tr><td><p>Year 3<sup>(2)</sup></p></td><td><p>449</p></td><td><p>92.9%</p><p>(90.1; 95.1)</p></td><td><p>448</p><p>(381; 527)</p></td><td><p>150</p></td><td><p>82.7%</p><p>(75.6; 88.4)</p></td><td><p>206</p><p>(147; 288)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>236</p></td><td><p>97.5%</p><p>(94.5; 99.1)</p></td><td><p>644</p><p>(531; 781)</p></td><td><p>86</p></td><td><p>93.0%</p><p>(85.4; 97.4)</p></td><td><p>296</p><p>(202; 433)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>162</p></td><td><p>85.2%</p><p>(78.8; 90.3)</p></td><td><p>248</p><p>(181; 340)</p></td><td><p>51</p></td><td><p>80.4%</p><p>(66.9; 90.2)</p></td><td><p>143</p><p>(80.5; 253)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>162</p></td><td><p>100%<br />(97.7; 100)</p></td><td><p>3760<br />(3268; 4326)</p></td><td><p>51</p></td><td><p>100%<br />(93.0; 100)</p></td><td><p>2956<br />(2041; 4282)</p></td></tr><tr><td><p>Month 1<sup>(1)</sup></p></td><td><p>673</p></td><td><p>100%<br />(99.5; 100)</p></td><td><p>13110<br />(11939; 14395)</p></td><td><p>224</p></td><td><p>100%<br />(98.4; 100)</p></td><td><p>8222<br />(6808; 9930)</p></td></tr><tr><td><p>Year 3<sup>(2)</sup></p></td><td><p>449</p></td><td><p>91.1%</p><p>(88.1; 93.6)</p></td><td><p>371</p><p>(309; 446)</p></td><td><p>150</p></td><td><p>86.0%</p><p>(79.4; 91.1)</p></td><td><p>390</p><p>(262; 580)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>236</p></td><td><p>88.6%</p><p>(83.8; 92.3)</p></td><td><p>249</p><p>(194; 318)</p></td><td><p>85</p></td><td><p>87.1%</p><p>(78.0; 93.4)</p></td><td><p>366</p><p>(224; 599)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>162</p></td><td><p>90.1%</p><p>(84.5; 94.2)</p></td><td><p>244</p><p>(182; 329)</p></td><td><p>51</p></td><td><p>82.4%</p><p>(69.1; 91.6)</p></td><td><p>177</p><p>(86.1; 365)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>162</p></td><td><p>100%<br />(97.7; 100)</p></td><td><p>8698<br />(7391 10235)</p></td><td><p>51</p></td><td><p>100%<br />(93.0; 100)</p></td><td><p>3879<br />(2715; 5544)</p></td></tr><tr><td><p>Month 1<sup>(1)</sup></p></td><td><p>678</p></td><td><p>99.9%<br />(99.2; 100)</p></td><td><p>8247<br />(7639; 8903)</p></td><td><p>224</p></td><td><p>100%<br />(98.4; 100)</p></td><td><p>2633<br />(2299; 3014)</p></td></tr><tr><td><p>Year 3<sup>(2)</sup></p></td><td><p>449</p></td><td><p>82.0%</p><p>(78.1; 85.4)</p></td><td><p>338</p><p>(268; 426)</p></td><td><p>150</p></td><td><p>30.0%</p><p>(22.8; 38.0)</p></td><td><p>16.0</p><p>(10.9; 23.6)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>236</p></td><td><p>86.0%</p><p>(80.9; 90.2)</p></td><td><p>437</p><p>(324; 588)</p></td><td><p>86</p></td><td><p>34.9%</p><p>(24.9; 45.9)</p></td><td><p>19.7</p><p>(11.8; 32.9)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>162</p></td><td><p>71.6%</p><p>(64.0; 78.4)</p></td><td><p>146</p><p>(97.6; 217)</p></td><td><p>51</p></td><td><p>43.1%</p><p>(29.3; 57.8)</p></td><td><p>16.4</p><p>(9.2; 29.4)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>162</p></td><td><p>100%<br />(97.7; 100)</p></td><td><p>11243<br />(9367; 13496)</p></td><td><p>51</p></td><td><p>100%<br />(93.0; 100)</p></td><td><p>3674<br />(2354; 5734)</p></td></tr><tr><td><p>Month 1<sup>(1)</sup></p></td><td><p>677</p></td><td><p>100%<br />(99.5; 100)</p></td><td><p>14087<br />(13168; 15069)</p></td><td><p>224</p></td><td><p>100%<br />(98.4; 100)</p></td><td><p>5066<br />(4463; 5751)</p></td></tr><tr><td><p>Year 3<sup>(2)</sup></p></td><td><p>449</p></td><td><p>93.1%</p><p>(90.3; 95.3)</p></td><td><p>740</p><p>(620; 884)</p></td><td><p>150</p></td><td><p>58.0%</p><p>(49.7; 66.0)</p></td><td><p>69.6</p><p>(44.6; 109)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>236</p></td><td><p>96.6%</p><p>(93.4; 98.5)</p></td><td><p>1000</p><p>(824; 1214)</p></td><td><p>86</p></td><td><p>66.3%</p><p>(55.3; 76.1)</p></td><td><p>125</p><p>(71.2; 219)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>162</p></td><td><p>90.7%</p><p>(85.2; 94.7)</p></td><td><p>447</p><p>(333; 599)</p></td><td><p>51</p></td><td><p>49.0%</p><p>(34.8; 63.4)</p></td><td><p>32.9</p><p>(17.1; 63.3)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>162</p></td><td><p>100%<br />(97.7; 100)</p></td><td><p>7585<br />(6748; 8525)</p></td><td><p>51</p></td><td><p>98.0%<br />(89.6; 100)</p></td><td><p>3296<br />(1999; 5434)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohort for each time point.</p><p>(1)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-036</p><p>(2)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-043</p><p>(3)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-101</p><p>(4)&nbsp;&nbsp;&nbsp; Blood sampling was performed 1 month after a booster dose at Year 10.</p><p>*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for the subsequent sampling time points.</p><p>&nbsp;</p><p>hSBA persistence was evaluated up to 5 years after vaccination in adolescents and adults initially vaccinated in Study MenACWY-TT-052 as shown in Table 14 (see section 4.4).</p><p>&nbsp;</p><p><strong>Table 14: hSBA* titres following a single dose of Nimenrix in adolescents and adults aged 11‑25&nbsp;years and persistence up to 5 years following vaccination (Studies&nbsp;MenACWY-TT-052/059)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:86%"><tbody><tr><td><p><strong>Meningococcal group</strong></p></td><td><p><strong>Time point</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8 (95% CI)</strong></p></td><td><p><strong>GMT (95% CI)</strong></p></td></tr><tr><td rowspan="3"><p><strong>A</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>356</p></td><td><p>82.0% (77.6; 85.9)</p></td><td><p>58.7 (48.6; 70.9)</p></td></tr><tr><td><p>Year 1<sup>(2)</sup></p></td><td><p>350</p></td><td><p>29.1% (24.4; 34.2)</p></td><td><p>5.4 (4.5; 6.4)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>141</p></td><td><p>48.9% (40.4; 57.5)</p></td><td><p>8.9 (6.8; 11.8)</p></td></tr><tr><td rowspan="3"><p><strong>C</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>359</p></td><td><p>96.1% (93.5; 97.9)</p></td><td><p>532 (424; 668)</p></td></tr><tr><td><p>Year 1<sup>(2)</sup></p></td><td><p>336</p></td><td><p>94.9% (92.0; 97.0)</p></td><td><p>172 (142; 207)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>140</p></td><td><p>92.9% (87.3; 96.5)</p></td><td><p>94.6 (65.9; 136)</p></td></tr><tr><td rowspan="3"><p><strong>W-135</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>334</p></td><td><p>91.0% (87.4; 93.9)</p></td><td><p>117 (96.8; 141)</p></td></tr><tr><td><p>Year 1<sup>(2)</sup></p></td><td><p>327</p></td><td><p>98.5% (96.5; 99.5)</p></td><td><p>197 (173; 225)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>138</p></td><td><p>87.0% (80.2; 92.1)</p></td><td><p>103 (76.3; 140)</p></td></tr><tr><td rowspan="3"><p><strong>Y</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>364</p></td><td><p>95.1% (92.3; 97.0)</p></td><td><p>246 (208; 291)</p></td></tr><tr><td><p>Year 1<sup>(2)</sup></p></td><td><p>356</p></td><td><p>97.8% (95.6; 99.0)</p></td><td><p>272 (237; 311)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>142</p></td><td><p>94.4% (89.2; 97.5)</p></td><td><p>225 (174; 290)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohort for persistence adapted for each time point.</p><p>(1)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-052</p><p>(2)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-059</p><p>*hSBA analysis performed at GSK laboratories</p><p><u>&nbsp;</u></p><p>rSBA titres were determined over a period of 10 years in subjects initially vaccinated with one dose of Nimenrix or ACWY-PS at 11 to 55 years of age in Study MenACWY-TT-015. Persistence of rSBA titres was evaluated in two extension studies: MenACWY-TT-020 (up to 5 years) and MenACWY-TT-099 (up to 10 years). Study MenACWY-TT-099 also evaluated the response to a single booster dose of Nimenrix administered 10 years following the initial vaccination with Nimenrix or ACWY-PS. Results are shown in Table 15.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:610px"><thead><tr><td colspan="8"><p><strong>Table 15:&nbsp;&nbsp; rSBA* titres following a single dose of Nimenrix (or ACWY-PS) in adolescents and adults aged 11-55 years, persistence up to 10 years, and post-booster administered 10&nbsp;years following initial vaccination (Studies MenACWY-TT-015/020/099)</strong></p></td></tr><tr><td rowspan="2"><p><strong>Meningo-coccal group</strong></p></td><td rowspan="2"><p><strong>Time point</strong></p></td><td colspan="3"><p><strong>Nimenrix</strong></p></td><td colspan="3"><p><strong>ACWY-PS vaccine</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>&ge;8</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMT</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td rowspan="5"><p><strong>A</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>323</p></td><td><p>100%<br />(98.9; 100)</p></td><td><p>4945<br />(4452, 5493)</p></td><td><p>112</p></td><td><p>100%<br />(96.8, 100)</p></td><td><p>2190<br />(1858, 2582)</p></td></tr><tr><td><p>Year 4<sup>(2)</sup></p></td><td><p>43</p></td><td><p>95.3%<br />(84.2; 99.4)</p></td><td><p>365<br />(226; 590)</p></td><td><p>17</p></td><td><p>76.5%<br />(50.1; 93.2)</p></td><td><p>104<br />(31.0; 351)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>51</p></td><td><p>84.3%<br />(71.4; 93.0)</p></td><td><p>190<br />(108; 335)</p></td><td><p>19</p></td><td><p>57.9%<br />(33.5; 79.7)</p></td><td><p>37.0<br />(12.6; 109)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>155</p></td><td><p>78.1%<br />(70.7; 84.3)</p></td><td><p>154<br />(108; 219)</p></td><td><p>52</p></td><td><p>71.2%<br />(56.9; 82.9)</p></td><td><p>75.1<br />(41.4; 136)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>155</p></td><td><p>100%<br />(97.6; 100)</p></td><td><p>4060<br />(3384; 4870)</p></td><td><p>52</p></td><td><p>100%<br />(93.2; 100)</p></td><td><p>3585<br />(2751; 4672)</p></td></tr><tr><td rowspan="5"><p><strong>C</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>341</p></td><td><p>99.7%<br />(98.4; 100)</p></td><td><p>10074<br />(8700, 11665)</p></td><td><p>114</p></td><td><p>100%<br />(96.8; 100)</p></td><td><p>6546<br />(5048; 8488)</p></td></tr><tr><td><p>Year 4<sup>(2)</sup></p></td><td><p>43</p></td><td><p>76.7%<br />(61.4; 88.2)</p></td><td><p>126<br />(61.6; 258)</p></td><td><p>17</p></td><td><p>41.2%<br />(18.4; 67.1)</p></td><td><p>16.7<br />(5.7; 48.7)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>51</p></td><td><p>72.5%<br />(58.3; 84.1)</p></td><td><p>78.5<br />(41.8; 147)</p></td><td><p>18</p></td><td><p>38.9%<br />(17.3; 64.3)</p></td><td><p>17.3<br />(6.0; 49.7)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>154</p></td><td><p>90.9%<br />(85.2; 94.9)</p></td><td><p>193<br />(141; 264)</p></td><td><p>52</p></td><td><p>88.5%<br />(76.6; 95.6)</p></td><td><p>212<br />(110; 412)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>155</p></td><td><p>100%<br />(97.6; 100)</p></td><td><p>13824<br />(10840; 17629)</p></td><td><p>52</p></td><td><p>98.1%<br />(89.7; 100)</p></td><td><p>3444<br />(1999; 5936)</p></td></tr><tr><td rowspan="5"><p><strong>W-135</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>340</p></td><td><p>99.7%<br />(98.4; 100)</p></td><td><p>8577<br />(7615; 9660)</p></td><td><p>114</p></td><td><p>100%<br />(96.8; 100)</p></td><td><p>2970<br />(2439; 3615)</p></td></tr><tr><td><p>Year 4<sup>(2)</sup></p></td><td><p>43</p></td><td><p>90.7%<br />(77.9; 97.4)</p></td><td><p>240<br />(128; 450)</p></td><td><p>17</p></td><td><p>17.6%<br />(3.8; 43.4)</p></td><td><p>8.3<br />(3.6; 19.5)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>51</p></td><td><p>86.3%<br />(73.7; 94.3)</p></td><td><p>282<br />(146; 543)</p></td><td><p>19</p></td><td><p>31.6%<br />(12.6; 56.6)</p></td><td><p>15.4<br />(5.7; 41.9)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>154</p></td><td><p>71.4%<br />(63.6; 78.4)</p></td><td><p>166<br />(107; 258)</p></td><td><p>52</p></td><td><p>21.2%<br />(11.1; 34.7)</p></td><td><p>10.9<br />(6.1; 19.3)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>155</p></td><td><p>100%<br />(97.6; 100)</p></td><td><p>23431<br />(17351; 31641)</p></td><td><p>52</p></td><td><p>98.1%<br />(89.7; 100)</p></td><td><p>5793<br />(3586; 9357)</p></td></tr><tr><td rowspan="5"><p><strong>Y</strong></p></td><td><p>Month 1<sup>(1)</sup></p></td><td><p>340</p></td><td><p>100%<br />(98.9; 100)</p></td><td><p>10315<br />(9317; 11420)</p></td><td><p>114</p></td><td><p>100%<br />(96.8; 100)</p></td><td><p>4574<br />(3864; 5414)</p></td></tr><tr><td><p>Year 4<sup>(2)</sup></p></td><td><p>43</p></td><td><p>86.0%<br />(72.1; 94.7)</p></td><td><p>443<br />(230; 853)</p></td><td><p>17</p></td><td><p>47.1%<br />(23.0; 72.2)</p></td><td><p>30.7<br />(9.0; 105)</p></td></tr><tr><td><p>Year 5<sup>(2)</sup></p></td><td><p>51</p></td><td><p>92.2%<br />(81.1; 97.8)</p></td><td><p>770<br />(439; 1351)</p></td><td><p>19</p></td><td><p>63.2%<br />(38.4; 83.7)</p></td><td><p>74.1<br />(21.9; 250)</p></td></tr><tr><td><p>Year 10<sup>(3)</sup><br />&nbsp;(Pre-booster)</p></td><td><p>154</p></td><td><p>86.4%<br />(79.9; 91.4)</p></td><td><p>364<br />(255; 519)</p></td><td><p>52</p></td><td><p>61.5%<br />(47.0; 74.7)</p></td><td><p>56.0<br />(28.8; 109)</p></td></tr><tr><td><p>&nbsp;(Post-booster)<sup>(3,4)</sup></p></td><td><p>155</p></td><td><p>100%<br />(97.6; 100)</p></td><td><p>8958<br />(7602; 10558)</p></td><td><p>52</p></td><td><p>100%<br />(93.2; 100)</p></td><td><p>5138<br />(3528; 7482)</p></td></tr></tbody></table><p>The analysis of immunogenicity was conducted on the ATP cohorts for 1 month and 5 years post vaccination and the booster ATP cohort.</p><p>(1)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-015</p><p>(2)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-020</p><p>(3)&nbsp;&nbsp;&nbsp; Study MenACWY-TT-099</p><p>(4)&nbsp;&nbsp;&nbsp; Blood sampling was performed 1 month after a booster dose at Year 10.</p><p>* rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for the subsequent sampling time points.</p><p><u>&nbsp;</u></p><p>In a separate study (MenACWY-TT-085), a single dose of Nimenrix was administered to 194 Lebanese adults aged 56 years and older (including 133 aged 56-65 years and 61 aged &gt;65 years). The percentage of subjects with rSBA titres (measured at GSK&rsquo;s laboratories) &ge;128 before vaccination ranged from 45% (group C) to 62% (group Y). Overall, at 1 month post-vaccination the percentage of vaccines with rSBA titres &ge;128 ranged from 93% (group C) to 97% (group Y). In the subgroup aged &gt;65 years the percentage of vaccines with rSBA titres &ge;128 at 1 month post-vaccination ranged from 90% (group A) to 97% (group Y).</p><p>&nbsp;</p><p><u>Booster response for subjects previously vaccinated with a conjugate meningococcal vaccine against <em>Neisseria meningitidis</em></u></p><p><u>&nbsp;</u></p><p>Nimenrix booster vaccination in subjects previously primed with a monovalent (MenC-CRM) or a quadrivalent conjugate meningococcal vaccine (MenACWY-TT) was studied in subjects from 12&nbsp;months of age onwards who received a booster vaccination. Robust anamnestic responses to the antigen(s) in the priming vaccine were observed (see Tables 6, 7, 11, 13, and 15).</p><p>&nbsp;</p><p><u>Response to Nimenrix in subjects previously vaccinated with a plain polysaccharide vaccine against <em>Neisseria meningitidis</em></u></p><p><em><u>&nbsp;</u></em></p><p>In Study MenACWY-TT-021 conducted in subjects aged 4.5-34 years, the immunogenicity of Nimenrix administered between 30 and 42 months after vaccination with a ACWY-PS vaccine was compared to the immunogenicity of Nimenrix administered to age-matched subjects who had not been vaccinated with any meningococcal vaccine in the preceding 10 years. An immune response (rSBA titre &ge;8) was observed against all four meningococcal groups in all subjects regardless of the meningococcal vaccine history. The rSBA GMTs were significantly lower in the subjects who had received a dose of ACWY-PS vaccine 30-42 months prior to Nimenrix, however 100% of subjects achieved rSBA titres &ge;8 for all four meningococcal groups (A, C, W-135, Y) (see section 4.4).</p><p>&nbsp;</p><p><u>Children (2-17 years) with anatomical or functional asplenia</u></p><p>&nbsp;</p><p>Study MenACWY-TT-084 compared immune responses to two doses of Nimenrix given 2 months apart between 43 subjects aged 2-17 years with anatomic or functional asplenia subjects and 43&nbsp;age‑matched subjects with normal splenic function. One month after the first vaccine dose and 1&nbsp;month after the second dose similar percentages of subjects in the two groups had rSBA titres &ge;8 and &ge;128 and hSBA titres &ge;4 and &ge;8.</p><p>&nbsp;</p><p><u>Impact of a single dose of Nimenrix</u></p><p><u>&nbsp;</u></p><p>In 2018, the Netherlands added Nimenrix to the national immunisation programme as a single dose for toddlers at 14 months of age to replace the meningococcal C conjugate vaccine. A catch-up campaign with a single dose of Nimenrix for adolescents 14-18 years of age also initiated in 2018, and it became routine in 2020 leading to a toddler and adolescent national immunisation programme. Within two years, the incidence of meningococcal disease caused by groups C, W, and Y was significantly reduced by 100% (95% CI: 14, 100) in individuals 14-18 years of age, 85% (95% CI: 32, 97) in all vaccine eligible ages (direct effect), and 50% (95% CI: 28, 65) in non-vaccine eligible ages (indirect effect). The impact of Nimenrix was primarily driven by a reduction in group W disease.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on local tolerance, acute toxicity, repeated dose toxicity, developmental/reproductive toxicity and fertility studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u>:</p><p>&nbsp;</p><p>Sucrose</p><p>Trometamol</p><p>&nbsp;</p><p><u>Solvent</u>:</p><p>&nbsp;</p><p>Sodium chloride</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
After reconstitution:

After reconstitution, the vaccine should be used promptly. Although delay is not recommended, stability has been demonstrated for 8 hours at 30°C after reconstitution. If not used within 8 hours, do not administer the vaccine.

Do not use Nimenrix after the expiry date which is stated on the Vial label after EXP: The expiry date refers to the last day of that month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder in a vial (type I glass) with a stopper (butyl rubber) and solvent in a pre-filled syringe with a stopper (butyl rubber).</p><p>Pack sizes of 1 and 10 with or without needles.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Instructions for reconstitution of the vaccine with the solvent presented in pre-filled syringe</u></p><p><u>&nbsp;</u></p><p>Nimenrix must be reconstituted by adding the entire content of the pre-filled syringe of solvent to the vial containing the powder.</p><p>To attach the needle to the syringe, refer to the below picture. However, the syringe provided with Nimenrix might be slightly different (without screw thread) than the syringe described in the picture. In that case, the needle should be attached without screwing.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holding the syringe <strong><u>barrel</u></strong> in one hand</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Syringe plunger</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Syringe barrel</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Syringe cap</p></td></tr></tbody></table><p>(avoid holding the syringe plunger),</p><p>&nbsp;</p><p>unscrew the syringe cap by twisting it anticlockwise.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To attach the needle to the syringe,</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; twist the needle clockwise into the syringe</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; until you feel it lock (See picture).</p><p>&nbsp;</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the needle protector, which on</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Needle protector</p></td></tr></tbody></table><p>occasion can be a little stiff.</p><p>&nbsp;</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add the solvent to the powder. After the addition of the solvent to the powder, the mixture should be well shaken until the powder is completely dissolved in the solvent.</p><p>&nbsp;</p><p>The reconstituted vaccine is a clear colourless solution.</p><p>The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.</p><p>After reconstitution, the vaccine should be used promptly.</p><p>&nbsp;</p><p>A new needle should be used to administer the vaccine.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Europe MA EEIG
Belgium 
 
 MANUFACTURED BY
Pfizer Manufacturing Belgium NV
Puurs, Belgium 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>